1. Introduction {#sec1}
===============

Periodontitis is an inflammatory disease of infectious origin characterized by progressive destruction of periodontal soft and hard tissues leading to tooth loss. The main symptoms comprise gingival inflammation, formation of periodontal pocket, alveolar bone loss, abscess, or tooth mobility \[[@B1]\]. The pathogenesis of periodontitis involves a complex interaction of immune and inflammatory cascades initiated by bacteria of the oral biofilm \[[@B2]\]. Persistent inflammation and dysbiosis worsen periodontal tissue damage, and the host response plays a vital role in this phenomenon contributing to tissue destruction \[[@B3]\].

The conventional treatment comprising scaling and root planing (SRP) presents limitations in certain cases involving deep periodontal pockets, inaccessible areas, or severe periodontitis \[[@B4]\]. Therefore, several adjunctive pharmacological therapeutics have been tested to improve its outcomes. In this context, systemic and local deliveries of drugs such as antibiotics, bisphosphonates, anti-inflammatory drugs, anticytokines, probiotics, and prebiotics have been tested so far to reduce bacterial load and to control inflammation \[[@B5]--[@B9]\]. Likewise, the use of statins in periodontal treatment has been explored recently \[[@B10]\]. Statins, or inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase), are a group of drugs, used primarily to treat hyperlipidemia and to prevent cardiovascular diseases \[[@B11]\]. After their discovery in the 70s, they have been widely prescribed worldwide \[[@B12]\]. They differ mainly in their ring structure, and these structural differences modify their pharmacological properties including hydrophilicity and lipophilicity. The lactone ring is present in an active form (already hydrolyzed) in all statins except for simvastatin, lovastatin, and mevastatin, in which the lactone ring is activated (hydrolyzed) in the liver. The lactone form of the statins enables their transport, metabolism, and clearance \[[@B13]\] ([Table 1](#tab1){ref-type="table"}).

Apart from their lipid-lowering properties, statins possess pleiotropic effects due to their anti-inflammatory, antioxidative, antibacterial, and immunomodulatory properties \[[@B14]--[@B17]\]. Statins have also been reported to have anabolic effects on the bone by augmenting bone morphogenetic protein-2 (BMP-2) expression, thus contributing towards the differentiation and activity of osteoblasts (OBs) \[[@B18]\]. In view of their beneficial properties, statins have been presented as new potential candidates for improving periodontal therapy outcomes \[[@B19], [@B20]\].

In several preclinical and clinical studies, statins have exhibited contradictory results \[[@B21]--[@B23]\] depending on the mode of delivery (local vs systemic), anatomy and severity of the lesions, type of disease, and treatment approach (nonsurgical vs surgical). Therefore, the aim of this literature review was to establish a better understanding of the prophylactic and therapeutic effects of all statin types administered locally or systemically as adjuvant to nonsurgical/surgical periodontal treatment in existing preclinical models and clinical settings and to explore the biological mechanisms underlying these healing and proregenerative effects in the management of periodontitis.

2. Methods {#sec2}
==========

2.1. Literature Search {#sec2.1}
----------------------

Studies published in English language only were included, and the last search was carried out in September 2018. Regarding studies performed on animal models and clinical trials, a systematic literature search was performed in the PubMed/MEDLINE and ScienceDirect databases. A hand search has also been performed after checking references of the identified articles. Concerning *in vivo* studies, the following keywords were used for the search: periodontitis OR periodontal disease OR alveolar bone loss OR periodontal attachment loss OR periodontal pocket AND simvastatin OR statin OR rosuvastatin OR atorvastatin OR cerivastatin OR mevastatin OR lovastatin OR pravastatin OR Fluvastatin OR pitavastatin OR Hydroxymethylglutaryl-CoA Reductase Inhibitors AND mouse OR dog OR pig OR rat OR rodent OR rabbit OR monkey OR in vivo. A study was considered eligible if it met the following criteria: (1) experimentally induced periodontitis (EIP) and/or acute/chronic periodontal defects (ACP), (2) treatment of EIP and/or ACP with statins (local or systemic or combination) with or without SRP or other periodontal treatment modalities, and (3) at least one periodontal parameter assessed as outcome. Exclusion criteria for *in vivo* studies were the following: (1) periapical lesions, (2) tooth extraction models, (3) orthodontic movements, (4) calvarial models, (5) long bone defects, and (6) drug-induced gingival enlargement.

Concerning clinical studies, the following keywords were used for the search: periodontitis OR periodontal disease OR alveolar bone loss OR periodontal attachment loss OR periodontal pocket AND simvastatin OR statin OR rosuvastatin OR atorvastatin OR cerivastatin OR mevastatin OR lovastatin OR pravastatin OR Fluvastatin OR pitavastatin OR Hydroxymethylglutaryl-CoA Reductase Inhibitors. A study was considered eligible if it met the following criteria: (1) randomized and controlled clinical trials, (2) cohort clinical studies, (3) longitudinal studies, (4) patients with diagnosis of chronic or aggressive periodontitis, (5) systemic or local administration of statins with nonsurgical or surgical periodontal treatment, and (6) at least one periodontal parameter: pocket depth (PD), clinical attachment level (CAL), bone loss (BL), or tooth loss (TL) assessed as outcome. Exclusion criteria for clinical studies were the following: (1) no follow-up, (2) no periodontal treatment, and (3) reviews, letters, and case reports.

2.2. Study Selection {#sec2.2}
--------------------

Titles and abstracts of the studies were screened independently by two reviewers (CP and FB) and categorized as suitable or not for inclusion. Full reports were reviewed independently for studies appearing to meet the inclusion criteria or for which there was insufficient information in the title and abstract to allow a clear decision. Disagreements between the authors were resolved after discussion with a third reviewer (OH).

2.3. Risk of Bias Assessment {#sec2.3}
----------------------------

Risk of bias was assessed using the Cochrane Collaboration\'s tool for assessing risk of bias which provided guidelines for the following parameters: sequence generation, allocation concealment method, blinding of the examiner, address of incomplete outcome data, and free of selective outcome reporting. The degree of bias was categorized as follows: low risk if all the criteria were met, moderate risk when only one criterion was missing, and high risk if two or more criteria were missing. Two reviewers (FB and CP) independently performed the quality assessment, and any disagreement was resolved by a third investigator (OH) (Supplemental [Table 1](#supplementary-material-1){ref-type="supplementary-material"}).

3. Results {#sec3}
==========

3.1. Effect of Statins on the Inflammatory-Immune Crosstalk {#sec3.1}
-----------------------------------------------------------

Localization of *periodontium* at the interface between the teeth and jaws exposes periodontal tissues to continuous bacterial challenge which could contribute to exacerbation of the immune response during periodontal wound healing. Recruitment of inflammatory cells at the periodontal site, including polymorphonuclear (PMN) leukocytes, macrophages, and lymphocytes, is associated to the release of a complex nexus of cytokines. When the inflammatory front migrates toward the alveolar bone, it stimulates osteoclastogenesis and subsequent alveolar bone destruction \[[@B24]\]. Therefore, the importance of inflammation control at the soft tissue level cannot be undermined.

The effects of statins on the inflammatory-immune crosstalk involved in the periodontal wound healing have been evaluated. Statins decrease the levels of proinflammatory cytokines (interleukin-1 beta (IL-1*β*), interleukin-8 (IL-8), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-*α*)) and increase the release of anti-inflammatory mediators (IL-10) and chemokines \[[@B25], [@B26]\]. There are several pathways implicated in the action of statins, notably suppression of HMG-CoA reductase, thereby inhibiting Rac and p21Ras phosphorylation. As Rac and p21Ras are coupled to the transcription of proinflammatory molecules via MAP kinase (MAPK) pathways, therefore, statins also suppress nuclear factor kappa B (NF-*κ*B) activation, thus reducing the expression of proinflammatory molecules \[[@B27]\] ([Figure 1](#fig1){ref-type="fig"}).

### 3.1.1. Effect of Statins on Inflammatory Molecules {#sec3.1.1}

*In vitro*, the effect of statins on inflammatory mediators\' secretion was demonstrated to be cell specific. For instance, in human oral epithelial cells \[[@B15]\] and OBs \[[@B28]\], statins reduced IL-6, IL-8 release, whereas, in T-cells \[[@B29], [@B30]\], statins increased the expression of IL-4, IL-5, IL-10 and IL-13. *In vivo*, statins confirmed the reduction of cyclooxygenase-2 (COX-2), prostaglandin E~2~ (PGE~2~), IL-1*β*, IL-6, IL-8, TNF-*α*, interferon-gamma (IFN-*γ*), C-reactive protein (CRP), colony-stimulating factors (CSF2, CSF3), recruitment of mononuclear inflammatory cells, and several Toll-like receptors (TLRs) in various EIP or ACP models \[[@B26], [@B31]--[@B35]\]. Clinical trials also corroborated the downregulation of inflammation by the use of statins, as demonstrated by increased IL-10 level in gingival crevicular fluid (GCF) from hyperlipidemic patients treated with statins \[[@B19]\].

### 3.1.2. Effect of Statins on Proresolution Molecules {#sec3.1.2}

Periodontal wound healing and regeneration involve a constant "tug-of-war" between the proinflammatory and anti-inflammatory/proresolution mediators \[[@B36], [@B37]\]. Anti-inflammatory effects of statins enhancing resolution of periodontal inflammation, that is, initiated by several endogenous chemical and lipid mediators, such as the lipoxins (LXs), resolvins (RVs), protectins, and maresins, could possibly explain the positive treatment outcomes \[[@B38], [@B39]\]. However, further studies need to explore the exact effect of statins on the proresolution mediators.

### 3.1.3. Effect of Statins on Host Modulation {#sec3.1.3}

Literature reports contradictory results regarding the effect of statins on different types of immune cells. For instance, in an ACP model, simvastatin did not change circulating white blood cell (WBC) counts in a study \[[@B33]\], whereas leukocyte infiltration was decreased by atorvastatin gavage in an EIP model \[[@B40]\]. Similarly, regulatory T (Treg) cells that control adaptive immunity against pathogens and activate other effector immune cells were reported to be regulated by statins. In this regard, atorvastatin and simvastatin demonstrated an increase in the number of human Treg cells and differentiation of CD4 into Treg *in vitro* \[[@B41], [@B42]\].

Furthermore, TLRs have an important role in the immune-inflammatory crosstalk with a consequent impact on periodontal wound healing response. In the context of periodontal treatment, targeting TLRs has been proposed as it could enhance antimicrobial properties, suppress adverse inflammation, or activate tissue repair \[[@B43]\]. Interestingly, simvastatin inhibited the stimulation of several TLRs (1, 2, 3, 4, 6, 7, and 9) by *Aggregatibacter actinomycetemcomitans* (*A.a*) LPS *in vivo*, reducing its capability to escape innate immune response \[[@B33]\]. Hence, statins play an instrumental role in the modulation of inflammatory and immune responses.

### 3.1.4. Inhibition of Major Histocompatibility Complex Class II (MHC-II) by Statins {#sec3.1.4}

In case of nonresolving periodontal lesions, bacterial antigens are processed and presented by antigen-presenting cells and macrophages. Such process is associated to massive immune cell recruitment implicated in tissular destruction \[[@B2]\]. In this regard, statins are able to inhibit MHC-II expression due to inhibition of the inducible promoter IV of the class II transactivator (CIITA) as observed in several cell types, including monocytes and macrophages \[[@B44]\]. This effect renders statins to have a potential host-modulating impact on periodontal treatment.

### 3.1.5. Lymphocyte Function-Associated Antigen-1 LFA1 Site Binding by Statins {#sec3.1.5}

Lymphocyte function-associated antigen-1 (LFA-1), an integrin with its main ligand intercellular adhesion molecule-1 (ICAM-1), is activated on the surface of fibroblasts (FBs) by IFN-*γ* and represents a critical phase in the early stage of inflammation. ICAM-1 regulates LFA-1-dependent neutrophil transmigration and recruitment to the inflammation site \[[@B45]\]. Several studies have demonstrated the inhibition of LFA-1 by statins in many inflammatory and immune diseases other than periodontitis. Statins inhibit ICAM-1 upregulation and chemotaxis of monocytes \[[@B46]\]. Lovastatin, simvastatin, and mevastatin, but not pravastatin, were able to inhibit the LFA-1/ICAM-1 interaction *in vitro* by binding to the L-site of LFA-1 \[[@B47]\]. In this way, statins limit the exacerbation of immune-mediated inflammatory response at the lesion site. However, the impact of statins on LFA-1 binding in the context of periodontal wound healing remains unexplored.

### 3.1.6. Effect of Statins on Nitric Oxide Synthase (NOS) {#sec3.1.6}

NOS plays an important role in host defence and homeostasis and has been implicated in the pathogenesis of periodontitis, where it is expressed in FBs, epithelial cells, rests of Malassez, macrophages, osteoclasts (OC), and vascular endothelial cells \[[@B48], [@B49]\]. In chronic periodontitis, bacterial challenge induces proinflammatory cytokine release and a higher expression of inducible NOS (iNOS) and NOS derived from FBs and WBCs that migrate to the periodontal lesion \[[@B50]--[@B52]\] leading to inflammation-mediated bone resorption \[[@B53]\]. Various studies demonstrated a NOS-inhibiting effect by the use of statins. For instance, *in vivo*, rosuvastatin significantly reduced inflammation-mediated tissue destruction and gingival iNOS expression \[[@B54]\].

Concerning the underlying mechanism of action, statins attenuate the production of reactive oxygen species (ROS) induced by NADPH oxidase by suppressing Rac\'s geranylation. Phosphatidylinositol-3 active kinase (PI3-Akt) is a kinase that phosphorylates and stimulates eNOS. Mevalonate is able to inhibit PI3-Akt; therefore, by reducing the concentration of mevalonate, statins upregulate eNOS-derived NO production resulting in vasorelaxation that leads to improved angiogenesis and wound healing response \[[@B27]\].

### 3.1.7. Effect of Statins on Matrix Metalloproteinases (MMPs) {#sec3.1.7}

MMPs degrade extracellular matrix proteins, especially collagen, contributing to the degradation of periodontal tissue including alveolar bone \[[@B55]\]. Most statins have been reported to potently inhibit the expression of MMP-1, MMP-8, and MMP-9 upregulated by LPS as demonstrated for simvastatin in mononuclear cells *in vitro* \[[@B56]\]. Moreover, *in vivo*, a decrease of MMP-1, MMP-2, MMP-8, and MMP-9 was observed by the use of statins \[[@B31], [@B57]--[@B59]\]. Thus, statins prevent periodontal tissue and alveolar bone destruction by inhibiting the release of MMPs.

3.2. Effect of Statins on Bone Metabolism {#sec3.2}
-----------------------------------------

Statins have an impact on bone metabolism through increase of osteogenesis, decrease of OB apoptosis, and osteoclastogenesis \[[@B60]\]. Statins allow periodontal regeneration via the Ras/Smad/extracellular signal-regulated kinase (Erk)/BMP-2 pathway that enhances bone formation \[[@B61]\] and by antagonizing TNF-*α* through Ras/Rho/mitogen-activated protein kinase (MAPK) that causes osteoclastic differentiation \[[@B62]\]. Moreover, they significantly increase OB differentiation factors such as alkaline phosphatase (ALP), osteocalcin (OCN), bone sialoprotein (BSP), BMP-2 \[[@B63]\], osteopontin (OPN), and vascular endothelial growth factor (VEGF) \[[@B64]\] ([Figure 2](#fig2){ref-type="fig"}).

### 3.2.1. Role of Statins in the Promotion of Osteogenesis {#sec3.2.1}

Inhibition of HMG-CoA by statins decreases prenylation of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GPP) leading to increased levels of BMP-2 and VEGF through the PI3-Akt pathway. Interestingly, both VEGF and BMP-2 regulate OB differentiation and bone formation during bone repair and regeneration \[[@B65], [@B66]\]. Concerning BMP, simvastatin and lovastatin increased the levels of BMP-2, consequently, increasing OB activity *in vitro* \[[@B58], [@B63]\]. Statins present a cost-effective option when compared with growth factors such as BMP-2 \[[@B67], [@B68]\].

Hydrophobic statins (simvastatin, atorvastatin, and cerivastatin) also increased mRNA expression of VEGF in OBs \[[@B69]\]. Likewise, simvastatin increased osteoprotegerin (OPG) expression in periodontal tissue \[[@B58]\] and enhanced matrix calcification in human bone marrow stem cells by diminishing the mean size of the fibroblastic colony-forming units (CFU-Fs) \[[@B70]\]. *In vivo*, statins stimulated bone growth and repair by increasing angiogenesis \[[@B71]\]. In particular, the lactone-form statins (lovastatin and simvastatin) stimulated OB differentiation of mouse periodontal ligament cells (PDLs) via the ERK1/2 pathway (phosphorylation) and enhanced intercellular matrix mineralization \[[@B63]\].

### 3.2.2. Role of Statins in the Inhibition of Bone Destruction {#sec3.2.2}

Statins act through certain pathways that avert bone degradation. Several clinical trials confirm the reduction of alveolar bone loss by statins, as an adjunct to SRP \[[@B72]\]. Many studies reported significantly decreased bone resorption by the use of simvastatin, rosuvastatin, and atorvastatin \[[@B26], [@B28], [@B32], [@B73]\]. Interestingly, simvastatin reduced TNF-*α*-induced synthesis of Cysteine-rich 61 (Cyr61) and chemokine ligand 2 (CCL2) \[[@B74]\] that are potential osteolytic mediators in inflammatory bone diseases, in human OB, thereby decreasing bone loss. Besides, statins increase bone formation by inhibiting OB apoptosis, augmenting TGF-*β* against the Smad3 signaling pathway. As an evidence, pitavastatin, mevastatin, and simvastatin induced the expression of Smad3 in nontransformed OBs (MC3T3-E1) \[[@B75]\]. Consequently, statins prevent bone destruction and also promote bone healing and regeneration.

### 3.2.3. Role of Statins in the Inhibition of Osteoclastogenesis {#sec3.2.3}

Statins suppress osteoclastogenesis through the OPG/receptor activator of the nuclear factor kappa-B ligand (RANKL)/RANK signaling pathway. Statins (simvastatin, atorvastatin, and fluvastatin) inhibited, *in vitro* and *in vivo*, the expression of the receptor activator of RANK which along with RANKL is required for the differentiation of OC precursors \[[@B26], [@B31], [@B33], [@B58], [@B76]\]. Nevertheless, IL-10 is also implicated in inhibiting bone resorption by preventing the RANK/RANKL pathway (\[[@B77]\]); hence, statins could potentially reduce the inflammation-mediated bone resorption \[[@B25]\]. Another mechanism for osteoclastogenesis involving unprenylated Rap GTP-binding protein 1A (Rap-1A), a RAS super family of small GTP-binding protein member, has been studied in the context of statins. Rosuvastatin, pravastatin, cerivastatin, and simvastatin caused accumulation of unprenylated Rap-1A in rabbit osteoclast-like cells and macrophages, inhibiting osteoclast-mediated resorption. Interestingly, hydrophilic statin (cerivastatin) was more effective than hydrophobic statin (rosuvastatin) to inhibit OC prenylation \[[@B78]\]. Additionally, the mRNA expression of cathepsin K, a key marker of OC differentiation, is reduced by simvastatin through inhibition of Src signaling and modulation of MAPK including ERK1/ERK2. Moreover, upregulation of AKT leads to a decrease of OC activity via RANKL and BMP-2 \[[@B79]\].

3.3. Antibacterial Effect of Statins {#sec3.3}
------------------------------------

Periodontitis is a polymicrobial disease involving keystone pathogen such as *Porphyromonas gingivalis* (*P.g*) that is able to hijack the adaptive immune response. Therefore, elimination of the periodontal pathogens is the cornerstone of periodontal treatment. Uncontrolled infection hinders periodontal wound healing and may worsen the therapeutic outcome by reducing the clinical attachment gain. Statins exhibit antimicrobial effects attributed to an increased bacterial clearance from the infection site as demonstrated in a model of sepsis ([Figure 3](#fig3){ref-type="fig"}) (\[[@B80]\]). Hence, statins could provide an additional benefit during periodontal wound healing ([Table 2](#tab2){ref-type="table"}).

Cholesterol is an integral component needed by bacteria for maintaining their membrane integrity. Statins can counter bacteria by inhibiting the intermediate in the isoprenoid biosynthesis pathway necessary for membrane stability, which is substituted by cholesterol and protects bacteria from the toxic effect of statins. Statins, therefore, kill bacteria directly and by lowering accessible host cholesterol content for bacterial growth and protection. Such effects may be due to the disruption of teichoic acid structures reducing biofilm formation (\[[@B81]\]). Statins display antibacterial activity towards anaerobic bacteria, including periodontal pathogens such as *A.a* and *P.g*. For instance, low concentration of simvastatin was proven to be effective against *A.a* and *P.g* even if *A.a* was more sensitive (MIC \< 1 *μ*g/mL) than *P.g* (MIC until 2 *μ*g/mL dilution) \[[@B82]\]. The hydrophobic nature of simvastatin may explain its antibacterial activity against periodontal pathogens where it disrupts the bacterial membrane in a "soap-like" manner causing its death \[[@B83]\]. Nevertheless, not all statins exhibit antibacterial activity. The degree of HMG-CoA reductase inhibition corresponds directly to the cholesterol-lowering capabilities of statins \[[@B84]\] but it does not seem commensurate with their antibacterial potency \[[@B85]\].

Some other mechanisms are modulated by the action of statins on lipoxin A4 (LXA4) production, a proresolving lipid mediator that enhances bacterial clearance, consequently reducing the severity of periodontal disease \[[@B86], [@B87]\]. Furthermore, the mechanistic target of rapamycin (mTOR) signaling, regulated principally by TLRs via two major pathways (NF-*κ*B-dependent pathway and a PI3-Akt-dependent pathway), is also involved in bacterial clearance \[[@B88]\]. It is known that statins inhibit isoprenoid synthesis, impeding intracellular signaling molecules like Rho or Rac \[[@B89]\].

Therefore, it is plausible that statins possess certain antibacterial properties that could facilitate periodontal treatment. However, since periodontitis is a polymicrobial disease, the susceptibility of various other periodontal pathogens to statins must also be evaluated.

3.4. Effects of Statins in Induced Periodontitis Models {#sec3.4}
-------------------------------------------------------

Statins have been tested in several induced periodontitis models to evaluate improvement in periodontal parameters and their underlying biological mechanisms. *In vivo*, 35 studies were identified based on the inclusion criteria ([Figure 4](#fig4){ref-type="fig"}), out of which 16 involved local statin delivery ([Table 3](#tab3){ref-type="table"}), 17 used systemic route ([Table 4](#tab4){ref-type="table"}), and 2 employed a combination of both modes ([Table 5](#tab5){ref-type="table"}). In the studies evaluating local statin application, 8 studies involved the treatment of EIPs while the remaining 8 investigated the treatment of ACP models, one of which was induced by LPS injection of *Escherichia coli* (*E. coli*) \[[@B90]\]. Concerning the systemic administration of statins ([Table 4](#tab4){ref-type="table"}), 14 out of the total 17 studies treated EIPs, whereas the 3 remaining studies involved ACP models by LPS injections of *A.a* \[[@B32], [@B33]\] and *P.g* into the gingiva \[[@B76]\].

Regarding the mode of periodontitis induction, in total, 24 out of 35 studies had EIP with ligatures (cotton, nylon, or silk), whereas 11 used ACP including the 4 studies where periodontitis was induced by bacterial LPS. Studies were mostly performed in rodents (Tables [3](#tab3){ref-type="table"}, [4](#tab4){ref-type="table"}, and [5](#tab5){ref-type="table"}). In ACP models, the surgically created lesions were mainly intrabony defects, fenestration defects, dehiscence defects, furcation class II defects, and 3-walled intrabony defects.

In 6 studies, animals with systemic diseases (i.e, osteoporosis \[[@B26], [@B91], [@B92]\], metabolic syndrome \[[@B32]\], cyclosporine A-associated alveolar bone loss \[[@B35]\], hyperlipidemia \[[@B54]\], or hypertension \[[@B93]\] were used to evaluate the effect of statins treatment. Overall, 22 studies involved treatment with simvastatin, 7 with atorvastatin, 3 with rosuvastatin, 2 with lovastatin, and only one with fluvastatin. Some studies investigated more than one type of statin. *In vivo*, the systemic dosage used ranged from 0.3 to 30 mg/kg with 20 mg/kg as the most commonly tested dose. The dose of locally delivered statins varied with the type of carrier/scaffold used ([Table 3](#tab3){ref-type="table"}). Five studies demonstrated insignificant improvements \[[@B94]--[@B98]\]. Interestingly, 3 of them involved surgical treatment of ACP models by local statin application \[[@B94], [@B96], [@B98]\] and one study employed nonsurgical local statin therapy \[[@B95]\], whereas only one EIP was treated with systemic statin delivery \[[@B97]\]. One study even demonstrated a negative impact of statin use \[[@B99]\].

3.5. Clinical Outcomes {#sec3.5}
----------------------

The selected studies evaluating the effect of statins in the context of periodontal treatment included 23 controlled and randomized clinical trials, 8 cohort studies, and 1 longitudinal study ([Figure 4](#fig4){ref-type="fig"}). Primary outcomes varied between improvement of clinical attachment level (CAL), reduction of pocket depth (PD), tooth loss, radiographic bone defect depth, periodontal inflamed surface area (PISA), and serum and/or GCF proinflammatory cytokines level. Most of the studies focused on the local administration (*n* = 25) of statins ([Table 6](#tab6){ref-type="table"}), while 7 investigated the impact of systemic route ([Table 7](#tab7){ref-type="table"}). Essentially, effects of statins have been evaluated as an adjunct to both nonsurgical and surgical treatments, mainly in the context of chronic periodontitis in healthy patients.

3.6. Statins as a Local Adjunct to Nonsurgical Periodontal Treatment {#sec3.6}
--------------------------------------------------------------------

The effect of local delivery of statins as an adjunct to nonsurgical periodontal therapy (SRP) was studied in 20 clinical trials ([Table 6](#tab6){ref-type="table"}). Atorvastatin and simvastatin have been the most commonly studied statins. Amongst the identified studies, 13 demonstrated a significant PD reduction, CAL gain, and IBD fill in healthy patients, 2 in well-controlled type II diabetes patients, and 3 in smokers. At contrary, in 2 studies, the test groups using atorvastatin or simvastatin did not show any significant differences when compared with the control \[[@B21], [@B100]\]. For instance, with simvastatin, the mean PD gain was 1.23 ± 0.57 mm for the control group versus 1.83 ± 0.07 mm for the test group (*p* = 0,112) and the mean CAL gain was 2.09 ± 0.08 mm for the control group versus 2.43 ± 0.01 mm for the test group (*p* = 0.889) after 45 days. Nevertheless, authors found a statistically significant reduction of PI, BOP, IL-6, and IL-8 levels \[[@B21]\].

Only 4 studies compared the outcomes obtained with more than one statin; however, contradictory results were observed. For instance, one study did not show any significant difference between atorvastatin and simvastatin \[[@B100]\], whereas better results were obtained with atorvastatin in another study \[[@B101]\]. Nevertheless, two studies highlighted greater efficacy with rosuvastatin in comparison with atorvastatin \[[@B20], [@B102]\].

Interestingly, studies that have investigated the effects of statin treatment on the biological markers from GCF showed that simvastatin administration reduced significantly IL-6, IL-8 and increased the anti-inflammatory IL-10 \[[@B21], [@B100], [@B103]\].

3.7. Statins as a Local Adjunct to Surgical Periodontal Treatment {#sec3.7}
-----------------------------------------------------------------

Statins have also been inspected for their role in the surgical treatment outcomes. In all identified studies where statins (simvastatin, atorvastatin, and rosuvastatin) were locally administered concomitant to surgical approach (including the use of biomaterials or PRF), a significant reduction of PD, improvement of CAL, and bone defect fill was achieved in the test group in comparison to the control group \[[@B104]--[@B108]\] ([Table 6](#tab6){ref-type="table"}). Amongst these studies, the mean difference of PD between the test and control groups ranged from 1.3 ± 0.21 mm to 2.51 ± 0.22 mm (*p* \< 0.001). Thus, the mean difference of CAL between the test and control groups ranged from 1.16 ± 0.09 mm to 2.35 ± 0.08 (*p* \< 0.001). Moreover, the mean difference of bone defect fill between the test and control groups ranged from 1.336 ± 0.714 to 3.08 ± 0.07 (*p* \< 0.001).

3.8. Impact of Systemic Administration of Statins on Nonsurgical Periodontal Treatment Outcomes {#sec3.8}
-----------------------------------------------------------------------------------------------

The impact of systemic administration of statins on nonsurgical periodontal treatment outcomes was evaluated in a few studies ([Table 7](#tab7){ref-type="table"}). From the 7 studies identified, 4 demonstrated significant improvements regarding reduction of PD, CAL gain, and/or tooth loss in comparison to the control group \[[@B56], [@B109]--[@B111]\]. At contrary, 3 other studies did not show any significant differences in periodontal outcomes between the statin-treated and control groups \[[@B112]--[@B114]\]. These discrepancies could be due to the very short follow-up of the abovementioned 3 studies (3 months) compared to the other ones (from 3 months to 7 years follow-up). Moreover, one of the studies did not compare the treatment group with a control group \[[@B110]\].

4. Discussion {#sec4}
=============

Statins exhibit multiple effects, including modulation of inflammatory-immune crosstalk, bone regeneration, and antibacterial activity, to promote periodontal wound healing and regeneration ([Figure 5](#fig5){ref-type="fig"}). They act through several closely interrelated pathways highlighting potential therapeutic targets. The hydrophobic or hydrophilic nature of statins determines their efficacy, action on periodontal pathogens, and treatment response and appears to be largely cell and tissue dependent \[[@B69], [@B78]\]. Further insight into this may help selecting the best statin.

Moreover, the mode of statin delivery also affects the treatment outcomes. Oral systemic administration of statins reduces periodontal inflammation and consequent tooth loss \[[@B111]\] but the low resultant dose available to the tissues after hepatic bypass renders them relatively less efficacious \[[@B60]\]. On the other hand, a higher dose to enhance efficacy can manifest systemic side effects such as statin-induced myopathy, hepatotoxicity, nephrotoxicity, pulmonary manifestations, ophthalmological manifestations, gastrointestinal hemorrhage risk, and oral manifestations (dryness, itch, bitterness, and cough) \[[@B115], [@B116]\]. Therefore, to avoid these side effects, various local application strategies have been tested that allow site-specific delivery reducing the required dose, frequency of application, and bioavailability in the blood \[[@B60], [@B117], [@B118]\], concomitantly improving patient compliance \[[@B119]\].

The development and selection of an optimal statin delivery carrier are crucial as it enhances the statin retention on the lesion and acts as a scaffold for cell growth and differentiation \[[@B120]\]; therefore, it should be capable to withstand the oral environment, continuous fluid exchange inside the pocket, and salivary influx.

Several studies demonstrate that anti-inflammatory properties of statins vary according to the type and dose of statin used \[[@B121]\]. On a cellular level, modulation of macrophage polarization from a proinflammatory M1 to a proresolution M2 phenotype by systemic delivery of immune modulatory drugs resolved persistent inflammation associated with chronic periodontitis \[[@B122]\]. In this context, statins\' ability to switch M1 to M2 to promote periodontal wound healing and regeneration needs to be explored. Furthermore, it is yet to be established if statin-induced reduction in plasma total cholesterol and LDL cholesterol levels in the periodontal space could decrease macrophage recruitment to improve the treatment outcome.

Despite the documented anti-inflammatory properties of statins, a local high-dose statin application causes considerable soft tissue inflammation \[[@B123]\]. Accordingly, studies determined that reducing the simvastatin dose from 2.2 mg to 0.5 mg reduced inflammation without compromising its bone growth potential \[[@B67]\]. A 10 mg/kg/day dose in rats is equivalent to 70 mg/day for humans, so it is a high systemic dose compared to that commonly used in clinical practice (20-40 mg/day) \[[@B124]\].

Concerning locally applied statins, most clinical studies investigated the 1.2% dose (mainly atorvastatin, simvastatin, and rosuvastatin) \[[@B20], [@B23], [@B125], [@B126]\]. Therefore, other doses should be tested to compare efficacy.

Most of the review articles have focused on the use of statins as adjunct to the nonsurgical SRP in clinical settings \[[@B127]--[@B129]\]. Here, this review encompasses the use of statins (local, systemic, or combination), alone or in addition to other drugs or scaffolds, in nonsurgical or surgical periodontal treatment *in vitro*, *in vivo*, and in clinical trials. However, the potential of statins in surgical periodontal therapy remains relatively less explored except for a few studies where treatment outcomes were improved, primarily, with the combination of some other regenerative agents such as allograft or PRF \[[@B105], [@B106]\]. Cognizant of the numerous studies involving statins, not all statin types have been studied so far; thus, exploring all natural and synthetic statins to compare their efficacy and safety could be instrumental.

Notably, 17 out of 32 clinical studies were carried out by the same group of researchers on similar population; therefore, generalizations should be drawn with caution. Additionally, in most studies involving statins, the follow-up period was no longer than 9 months \[[@B103], [@B130]\]. Hence, it is imperative to follow clinical studies for periods longer than those commonly investigated so as to achieve a deeper and more genuine insight into their long-term benefits. Discrepancies amongst outcomes between time points are of importance to clearly conclude. For instance, the meta-analysis performed by Sinjab et al. \[[@B131]\] declared the outcomes of the control group of a study \[[@B20]\] to be better by considering the data up to 6 months follow-up, whereas the meta-analysis performed by Ambrósio et al. regarded the treatment group of the same study to have better outcomes as the follow-up data until 9 months was taken into account \[[@B132]\].

Moreover, the studies carried out so far mainly involved hyperlipidemic patients, diabetic patients, or smokers. Systemic diseases, such as obesity or metabolic syndrome, have been linked with periodontitis \[[@B133]\]. It has been demonstrated that such conditions modify significantly the host response to periodontal pathogens \[[@B134]\] but also could impaired treatment response. For instance, in a rat model of metabolic syndrome, the effects induced by statins in rats with metabolic syndrome were different in comparison with rats without \[[@B32]\] highlighting the potential modulation of pharmacologic effect due to the systemic condition. Even if clinical trials performed in diabetes patients or exhibiting hyperlipidemia showed promising results when statins were administered concomitantly to nonsurgical periodontal treatment \[[@B56], [@B110], [@B113], [@B114]\], more studies are required to better understand the differential biological mechanisms modulated by statin\'s administration. It would also be of importance to assess statins\' tolerance and efficacy in subjects with different systemic conditions where periodontal treatment response is impaired (e.g., liver diseases, kidney dysfunction, and immunocompromised states).

In clinical trials, the local application of statins with surgical periodontal treatment always showed significant improvements in periodontal parameters \[[@B105], [@B106]\]. However, *in vivo*, statin application in ACP models showed contradictory results \[[@B99]\] which could be explained by the limitations of animal models to simulate conditions identical to human periodontal disease. Nevertheless, as a direct optimization of treatment protocols in humans is not ethically permissible, the utility of preclinical models to get directions and overall assessment of the expected treatment outcomes in clinical scenarios cannot be undermined.

Concerning the systemic administration of statins, a study reported that using a combination of two pharmacokinetically different statins (20 mg/day of atorvastatin plus 40 mg/day of pravastatin) in hyperlipidemic patients for one year improved their lipid profiles compared to those on monotherapies \[[@B135]\]. Besides, a case of a hyperlipidemic patient experiencing certain side effects with a high dose of systemic simvastatin who could well tolerate a combination of reduced doses of simvastatin and rosuvastatin instead has also been reported \[[@B136]\]. To the best of our knowledge, no two statins have been combined for periodontal treatment so far; nonetheless, combination of two statins could be tested for its impact on periodontal treatment response.

Likewise, the impact of incorporating statins with antimicrobial agents, growth factors, or other proregenerative molecules within a local application system could be studied as adjunct to SRP. Statin integration into gels \[[@B21]\] or dentifrice \[[@B137]\] could enhance ease of application and patient\'s compliance and could be potentially beneficial in the maintenance phase to counter periodontal breakdown that persists after conventional periodontal treatment. The literature does not report the impact of statins on patients with extremely poor oral hygiene; nonetheless, it could be interesting to explore the impact of statins on oral hygiene indicators.

5. Conclusion {#sec5}
=============

Statins have been studied in depth in the context of bone regeneration, but soft tissue healing remains relatively less explored. Further research into it could present statins as a potential adjunctive therapeutic strategy with a positive impact on both hard and soft periodontal tissue healing. Furthermore, the impact of statins on proresolution molecules has not been investigated in the context of periodontal wound healing and regeneration. This could unveil new vistas for statins as regenerative therapeutics. Since all available statins have not been tested yet, new studies need to evaluate the impact of other statins on antibacterial, inflammatory, immune, and osteoprogenitor responses. To conclude, choosing an optimum dose of statins, based on the mode of drug delivery and the carrier employed, may enhance the positive impact of statins on the periodontal treatment outcomes. Moreover, combining statins with growth factors or other drugs in an efficient carrier system may be beneficial to promote periodontal regeneration.

The authors are very grateful to the Agence Nationale de la Recherche (The French National Research Agency) (nos. ANR-14-CE16-0025-04 and ANR-17-CE17-0024-01) for their valuable support.

M1:

:   First molar

M2:

:   Second molar

M3:

:   Third molar

mPEG:

:   Polyethylene glycol monomethyl ether

PDLLA-PLGA:

:   Poly-(d,l-lactide) and poly-(d,l-lactide-co-glycolide

BSA:

:   Bovine serum albumin

PDGF:

:   Platelet-derived growth factor

PM:

:   Premolar

PDL:

:   Periodontal ligament cells

EGCG:

:   Epigallocatechin-3-gallate

CS:

:   Chitosan

BALP:

:   Bone alkaline phosphatase

LPS:

:   Lipopolysaccharide

PBS:

:   Phosphate buffered saline

ALN-CD:

:   Alendronate-*β*-cyclodextrin

SIM:

:   Simvastatin

CEJ:

:   Cementoenamel junction

HA:

:   Hydroxyapatite

TGF-*β*:

:   Transforming growth factor beta

*E. coli*:

:   *Escherichia coli*

PPi:

:   Isopropyl alcohol

TRAP:

:   Tartrate-resistant acid phosphatase

GSH:

:   Glutathione

MDA:

:   Malondialdehyde

MPO:

:   Myeloperoxidase

GIOP:

:   Glucocorticoid-induced osteoporosis

DKK1:

:   Dickkopf-related protein

CAT:

:   Enzyme catalase

SOD:

:   Enzyme superoxide dismutase

MMPs:

:   Matrix metalloproteinases

MCP:

:   Monocyte chemotactic protein

CSF:

:   Colony-stimulating factor

*A*.*a*:

:   *Aggregator actinomycetemcomitans*

*P.g*:

:   *Porphyromonas gingivalis*

COX:

:   Cyclooxygenase

ALP:

:   Alkaline phosphatase

AST:

:   Aspartate aminotransferase

ALT:

:   Alanine aminotransferase

IP:

:   Intraperitoneal

TG:

:   Triglyceride

ATV:

:   Atorvastatin

PD:

:   Pocket depth

RANKL:

:   Receptor activator of the NF-*κ*B ligand

RANK:

:   Receptor activator of NF-*κ*B

OPG:

:   Osteoprotegerin

OPN:

:   Osteopontin

BV/TV:

:   Bone volume/tissue volume

CAL:

:   Clinical attachment level

SRP:

:   Scaling and root planing

INFRA:

:   Radiographic infrabony defect fill

MF:

:   Metformin

DDR:

:   Defect depth reduction

DFDBA:

:   Demineralized freeze-dried bone allograft

OFD:

:   Open flap debridement

BOP:

:   Bleeding on probing

GI:

:   Gingival index

PI:

:   Plaque index

mSBI:

:   Modified sulcus bleeding index

IBD:

:   Intrabony defect

PRF:

:   Platelet-rich fibrin

PISA:

:   Periodontal inflamed surface area

LDL-C:

:   Low-density lipoprotein cholesterol

HDL-C:

:   High-density lipoprotein cholesterol

OB:

:   Osteoblasts

OC:

:   Osteoclasts

EIP:

:   Experimentally induced periodontitis

ACP:

:   Acute/chronic periodontal defect

NOX:

:   Nitrate/nitrite levels

VEGF:

:   Vascular endothelial growth factor.
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###### 

Risk of bias assessment of included clinical studies.

###### 

Click here for additional data file.

![Effect of statins on the inflammatory-immune crosstalk. Direct LFA1 site binding by lipophilic statins decreases ICAM-1 presentation leading to reduced leukocyte chemotaxis and antigen presentation. Statins inhibit MHC-II induction by IFN-*γ* leading to decreased T-cell activation. Statins lower mevalonate release, leading to resolution of inflammation via the ERK, MAPK, and PI3K-Akt pathways.](MI2019-6367402.001){#fig1}

![Effects of statins on several pathways involved in bone metabolism. Statins decrease osteoclastogenesis via RANK/RANKL and NF-*κ*B signaling. Statins promote osteogenesis by increasing VEGF, BMP2, and TGF-*β* expression through the PI3-Akt pathway. Statins prevent inflammation-mediated bone resorption by decreasing TNF-*α*, via TNFR.](MI2019-6367402.002){#fig2}

![Antibacterial effect of statins. Statins arrest bacterial growth and disrupt their membrane stability by decreasing cholesterol. Statins increase bacterial clearance by decreasing NF-*κ*B and ROS signaling (via the PI3K-Akt and NADPH oxidase pathways, respectively) and by enhancing proresolution molecule release.](MI2019-6367402.003){#fig3}

![Selection of the studies.](MI2019-6367402.004){#fig4}

![Pleiotropic effects of statins in the context of periodontitis management. Statin biological properties might be of interest for the management of periodontitis as they act on each tissular compartment and mechanisms including inflammatory-immune crosstalk, bone metabolism and bacterial clearance.](MI2019-6367402.005){#fig5}

###### 

Physical properties of different types of statins.

  Drug           Source      Solubility    Molecular mass (Da)
  -------------- ----------- ------------- ---------------------
  Atorvastatin   Synthetic   Lipophilic    1209.42
  Simvastatin    Natural     Lipophilic    418.6
  Lovastatin     Natural     Lipophilic    404.5
  Mevastatin     Natural     Lipophilic    390.52
  Pravastatin    Natural     Hydrophilic   446.52
  Fluvastatin    Synthetic   Lipophilic    411.47
  Cerivastatin   Synthetic   Lipophilic    459.56
  Pitavastatin   Synthetic   Lipophilic    421.46
  Rosuvastatin   Synthetic   Hydrophilic   481.54

###### 

Representative *in vitro* studies evaluating the impact of statins on periodontal pathogens.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Local drug delivery                                                                                                                                                                                                              
  --------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------- ---------- --------------------------------------------------------------------------------------------------------
  \[[@B82]\]            MIC was determined against *P.g* (ATCC 33277) and *A.a* (ATCC 25586) using serial dilution method                                                       Simvastatin, 1 *μ*g/mL to 500 *μ*g/mL   ↘ *P.g*\   Simvastatin had an antibacterial effect against the keystone pathogens involved in periodontal disease
                                                                                                                                                                                                                        ↘ *A.a*    

                                                                                                                                                                                                                                   

  \[[@B138]\]           *A.a* (ATCC 43719), *P*. *nigrescens* (ATCC 33563), or *P.g* (ATCC 33277) were cultured on a trilayer functional CS membrane with EGCG and lovastatin   Lovastatin 0.1, 0.5, 1, and 2 mg        ↘ *P.g*\   Lovastatin had an antibacterial effect against periodontopathogenic bacteria
                                                                                                                                                                                                                        ↘ *A.a*    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

*In vivo* studies evaluating the impact of local statin administration on periodontal wound healing.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Local drug delivery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  --------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \[[@B139]\]           Rats (retired female breeder)\                                                                                                                                                                                                                                                                                                                                                                                   Nonsurgical treatment (therapeutic)\                                                                                                                                                                                                                      ↗ amount of uninflamed connective tissue in the M1-M2 interproximal area\                                                         Simvastatin limited periodontal breakdown by reducing bone loss and the extent of gingival inflammation
                        EIP by ligatures\                                                                                                                                                                                                                                                                                                                                                                                                Simvastatin prodrug 0.5 mg, 1.0 mg, and 1.5 mg\                                                                                                                                                                                                           ↘ bone loss, especially with 1.5 mg SIM/SIM-mPEG\                                                                                 
                        Maxillary right M2                                                                                                                                                                                                                                                                                                                                                                                               Local injections of the drug/SIM/SIM-mPEG carrier\                                                                                                                                                                                                        ↘ percentage of neutrophils                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                         10 *μ*L into the palatal gingiva between maxillary M1 and M2\                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                         Three weekly injections until euthanasia                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  \[[@B73]\]            Rats (male)\                                                                                                                                                                                                                                                                                                                                                                                                     Surgical treatment (therapeutic)\                                                                                                                                                                                                                         ↗ neo-osteogenesis\                                                                                                               Simvastatin promoted osteogenic differentiation, reduced inflammation, and facilitated osteogenesis. Sequential PDGF-simvastatin delivery was able to accelerate osteogenesis, bone maturation, fiber realignment, and cementogenesis of the periodontal apparatus, thus accelerating periodontal regeneration
                        ACP (maxillary bone defect)\                                                                                                                                                                                                                                                                                                                                                                                     Simvastatin 1 mg\                                                                                                                                                                                                                                         ↗ bone mineral density\                                                                                                           
                        Maxillary M1 extraction followed by socket healing, preparation of a critical-sized periodontal defect (2.0 mm diameter and 1.0 mm depth) on the mesial aspect of the M2, and manual removal of the residual bone and cementum on mesial aspect of M2                                                                                                                                                            Encapsulated in double-walled PDLLA-PLGA microspheres\                                                                                                                                                                                                    ↗ bone volume fraction\                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                         Combinations: simvastatin-BSA, simvastatin-PDGF, simvastatin                                                                                                                                                                                              ↗ number and thickness of trabeculae\                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ↘ trabecular separation\                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ↗ cementogenesis of the periodontal apparatus\                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ↘ inflammatory cell infiltration                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  \[[@B94]\]            Rats (male)\                                                                                                                                                                                                                                                                                                                                                                                                     Surgical treatment (therapeutic)\                                                                                                                                                                                                                         ↗ neo-osteogenesis (histologically)\                                                                                              Simvastatin histologically improved bone healing but better healing response was observed in the group receiving PDGF
                        ACP (tooth-associated alveolar bone defect model) extraction of M1 followed by 4 weeks of socket healing, preparation of a critical-sized intrabony periodontal defect in the M1 edentulous ridge next to the mesial aspect of the M2 finished by a 2.6 mm diameter and 1.0 mm deep osteotomy (completely removing the mesial wall of the osteotomy), and cementum removal (to expose the mesial aspect of M2)   Simvastatin 1 mg\                                                                                                                                                                                                                                         PDL fibers not inserted on the root surface (mainly parallel)\                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                         PDLLA-PLGA hybrid microspheres encapsulating simvastatin/PDGF/BSA to fill the defects                                                                                                                                                                     ↗ bone volume fraction % (not significant)                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  \[[@B95]\]            Rats (female)\                                                                                                                                                                                                                                                                                                                                                                                                   Nonsurgical treatment (therapeutic)\                                                                                                                                                                                                                      ↗ insignificant improvement of bone fill compared to other groups\                                                                Simvastatin had a local bone healing effect which can be augmented by addition of certain other regenerative molecules like ALN
                        ACP (fenestration defects)\                                                                                                                                                                                                                                                                                                                                                                                      Simvastatin 0.5 mg\                                                                                                                                                                                                                                       New cementum formation (not significant)\                                                                                         
                        Defects 2 mm high, 4 mm wide, and 1.5 mm deep over mandibular molar roots                                                                                                                                                                                                                                                                                                                                        Local injection of 0.5 mg SIM per site dissolved in 70% ethanol or as SIM-ALN-CD\                                                                                                                                                                         But better bone healing response after systemic ALN administration followed by simvastatin injections                             
                                                                                                                                                                                                                                                                                                                                                                                                                                         Three weekly injections\                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                         Treatment started 15 days after the defect preparation                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  \[[@B138]\]           Dogs (male)\                                                                                                                                                                                                                                                                                                                                                                                                     Surgical treatment (therapeutic)\                                                                                                                                                                                                                         ↗ new bone formation in the EGCG14-CS-lovastatin 1 group (62.03%) \> BioMend® group (46.07%) \> control group (42.32%)\           The trilayer functional CS membrane with EGCG and lovastatin enhanced periodontal regeneration and bone formation rate
                        ACP (maxillary bone defect)\                                                                                                                                                                                                                                                                                                                                                                                     Lovastatin 0.1, 0.5, 1, or 2 mg per trilayer functional CS with the EGCG membrane area (cm^2^)                                                                                                                                                            Evidence of new cementum deposition observed on the root surface\                                                                 
                        Extraction of all maxillary PM2 followed by healing and preparation of one-walled intrabony defects (4 × 5 × 4 mm: buccolingual, mesiodistal, and depth, respectively) on the mesial and distal sides of maxillary bilateral PM1\                                                                                                                                                                                                                                                                                                                                                                                                                                          No inflammatory cell infiltrate was noted in the EGCG~14~-CS-lovastatin 1 group\                                                  
                        Removal of residual cementum by SRP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Fibrous connective tissue approximated to the surgical defect                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  \[[@B140]\]           Dogs (male)\                                                                                                                                                                                                                                                                                                                                                                                                     Nonsurgical treatment (therapeutic)\                                                                                                                                                                                                                      ↗ new deposits of cementum on the root surface\                                                                                   PLGA-lovastatin-chitosan-tetracycline nanoparticles showed a good osteogenic potential. They promoted new bone and cementum formation
                        ACP (maxillary bone defect)\                                                                                                                                                                                                                                                                                                                                                                                     Lovastatin 4 mg dissolved in chloroform to form a 3 wt % PLGA solution\                                                                                                                                                                                   ↗ active plasmacytoid osteoblastic rimming along the trabecular surface of the bone adjacent to the defect\                       
                        Extraction of maxillary 2^nd^ and 3^rd^ incisors followed by 8 weeks of socket healing and, later, preparation of three-walled intrabony defects (4 × 4 × 5 mm: buccolingual, mesiodistal, and depth, respectively) on the mesial side of maxillary bilateral canines\                                                                                                                                           Local injections of PLGA-lovastatin-CS-tetracycline 0.3% nanoparticles prepared as a hydrogel by mixing with gelatin (10 mg/100 mm^3^) to fill the defects                                                                                                ↗ percentage of new bone formation (41.32%)\                                                                                      
                        Removal of residual cementum by SRP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        No evident inflammation                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  \[[@B96]\]            Rats (male)\                                                                                                                                                                                                                                                                                                                                                                                                     Surgical treatment (therapeutic)\                                                                                                                                                                                                                         ↘ marrow spaces in simvastatin-treated defects\                                                                                   Simvastatin gel improved the quality of the new bone and decreased bone resorption
                        ACP (mandibular bone defect)\                                                                                                                                                                                                                                                                                                                                                                                    Simvastatin 2.5% gel\                                                                                                                                                                                                                                     ↗ collagen fibril organization\                                                                                                   
                        Preparation of surgical defects 0.8 mm in diameter through the alveolar bone over the mesiobuccal root of the mandibular M1 bilaterally                                                                                                                                                                                                                                                                          Defect was filled with 2.5% simvastatin gel\                                                                                                                                                                                                              ↗ OPN in bone matrix\                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                         Single topical application                                                                                                                                                                                                                                ↗ alveolar bone regeneration                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  \[[@B99]\]            Dogs (males and females)\                                                                                                                                                                                                                                                                                                                                                                                        Nonsurgical treatment (therapeutic)\                                                                                                                                                                                                                      ↗ edentulous ridge thickness (29% greater with simvastatin)\                                                                      Simvastatin was not appropriate for the treatment of class II furcation defects. However, it improved bone healing in intrabony defects and edentulous ridges significantly
                        ACP (mandibular bone defect)\                                                                                                                                                                                                                                                                                                                                                                                    Simvastatin 0.5 mg or 2.0 mg in 30 *μ*L methylcellulose gel\                                                                                                                                                                                              ↗ bone loss in class II furcation defects\                                                                                        
                        Preparation of bilateral 3-walled intrabony defects (4 × 4 × 4 mm) distal of the mandibular PM2 and mesial of the PM4 and class II furcation defects at the buccal furcation of the mandibular M1 measuring 4 mm occlusal apically and 4 mm buccolingually followed by healing and SRP of defect sites                                                                                                           Three weekly injections                                                                                                                                                                                                                                   ↗ length of new cementum in the interproximal intrabony defect\                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ↗ bone height with simvastatin (2 mg)\                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   No new cementum was observed in furcations                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  \[[@B22]\]            Rats (male)\                                                                                                                                                                                                                                                                                                                                                                                                     Nonsurgical treatment (therapeutic)\                                                                                                                                                                                                                      ↘ IL-1*β*, IL-6, and IL-8\                                                                                                        Atorvastatin with chitosan downregulated inflammation-mediated bone resorption
                        EIP by ligatures\                                                                                                                                                                                                                                                                                                                                                                                                Atorvastatin\                                                                                                                                                                                                                                             ↗ IL-10 (time dependent)\                                                                                                         
                        Maxillary M2 bilaterally                                                                                                                                                                                                                                                                                                                                                                                         2% *w*/*v* containing CS gel\                                                                                                                                                                                                                             ↘ alveolar bone resorption (significantly with ATV + CS application and insignificantly with ATV alone)\                          
                                                                                                                                                                                                                                                                                                                                                                                                                                         Local 100 *μ*L volume application every other day until euthanasia                                                                                                                                                                                        ↘ attachment loss\                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Improvement of inflammatory and osteoclastic activity score over time                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  \[[@B90]\]            Rats (female)\                                                                                                                                                                                                                                                                                                                                                                                                   Nonsurgical treatment (preventative)\                                                                                                                                                                                                                     ↗ bone preservation during experimental periodontitis by prophylactic SIM-ALN-CD injection\                                       Simvastatin protected against alveolar bone loss and soft tissue inflammation
                        EIP by injection of *E. coli* LPS\                                                                                                                                                                                                                                                                                                                                                                               Simvastatin\                                                                                                                                                                                                                                              ↘ subsulcular inflammation\                                                                                                       
                        10 *μ*L of endotoxin injection\                                                                                                                                                                                                                                                                                                                                                                                  0.5 mg of simvastatin and 3.75 mg of SIM-ALN-CD in H2O\                                                                                                                                                                                                   ↘ alveolar bone loss\                                                                                                             
                        (1 mg/mL of LPS in PBS) between M1 and M2                                                                                                                                                                                                                                                                                                                                                                        Three weekly 12 *μ*L injection bilaterally into the palatal/interproximal gingiva of M1 and M2\                                                                                                                                                           ↘ OC number                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                         Treatment started one week before induction                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  \[[@B98]\]            Dogs (female)\                                                                                                                                                                                                                                                                                                                                                                                                   Surgical treatment (therapeutic)\                                                                                                                                                                                                                         ↗ width of new bone in edentulous ridge\                                                                                          Simvastatin improved new bone formation where periosteum existed and did not induce severe side effects except for moderate swelling that, eventually, subsided
                        ACP (mandibular bone defect)\                                                                                                                                                                                                                                                                                                                                                                                    Simvastatin\                                                                                                                                                                                                                                              Distance between CEJ and the alveolar crest was more coronal in dehiscence defects treated with simvastatin (insignificant)\      
                        Preparation of dehiscence defects (5 × 3 mm) bilaterally on the lateral aspect of the mandibular PM2 mesial roots and removal of root cementum\                                                                                                                                                                                                                                                                  Graft surgery with HA grafts bilaterally covered with resorbable bilayer collagen membranes hydrated with 10 mg simvastatin (graft surgery performed at the time of defect preparation)\                                                                  Three weeks post-op after simvastatin injection (firm swelling about 1 × 1 cm to 3.5 × 3.5 cm in size), disappeared in 2 months   
                        Split-mouth design                                                                                                                                                                                                                                                                                                                                                                                               Local injection 10 mg SIM (0.5 mg/kg) in ethanol (100 *μ*L)\                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                         Three weekly injections (one week after the graft surgery and defect preparation)                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  \[[@B59]\]            Rats (male)\                                                                                                                                                                                                                                                                                                                                                                                                     Nonsurgical treatment (therapeutic)\                                                                                                                                                                                                                      ↘ MMP-8 expression\                                                                                                               Simvastatin reduced periodontal bone loss
                        EIP by ligatures\                                                                                                                                                                                                                                                                                                                                                                                                Simvastatin\                                                                                                                                                                                                                                              ↘ bone loss                                                                                                                       
                        Left mandibular M1                                                                                                                                                                                                                                                                                                                                                                                               1 mg/mL\                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                         (Natrosol + simvastatin gel solution) into the periodontal pocket\                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                         SRP and irrigation with simvastatin\                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                         Single injection                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  \[[@B141]\]           Rats (male)\                                                                                                                                                                                                                                                                                                                                                                                                     Nonsurgical treatment (therapeutic)\                                                                                                                                                                                                                      ↗ ALP activity\                                                                                                                   Simvastatin increased bone regeneration and reduced inflammation
                        EIP by ligatures\                                                                                                                                                                                                                                                                                                                                                                                                Simvastatin\                                                                                                                                                                                                                                              ↗ bone nodule formation\                                                                                                          
                        Maxillary M2                                                                                                                                                                                                                                                                                                                                                                                                     0.2 mg in 50 *μ*L PBS topically injected into the buccal gingivae\                                                                                                                                                                                        No inflammatory cells around the new bone\                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                         Twice a week for 70 days                                                                                                                                                                                                                                  ↘ bone loss\                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Simvastatin recovered the ligature-induced alveolar bone resorption (46% reversal of bone height)                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  \[[@B142]\]           Rats (male)\                                                                                                                                                                                                                                                                                                                                                                                                     Nonsurgical treatment (preventative)\                                                                                                                                                                                                                     ↘ bone loss\                                                                                                                      Simvastatin reduced bone loss
                        EIP by ligatures\                                                                                                                                                                                                                                                                                                                                                                                                Simvastatin 0.5 mg/kg body weight orally\                                                                                                                                                                                                                 ↘ carbonylated proteins in gingiva                                                                                                
                        Mandibular left M1                                                                                                                                                                                                                                                                                                                                                                                               Followed by laser therapy\                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                         Treatment started 1 day before induction and daily until euthanasia                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  \[[@B91]\]            Rats (female ovarectomized)\                                                                                                                                                                                                                                                                                                                                                                                     Nonsurgical treatment (protective)\                                                                                                                                                                                                                       ↘ periodontal breakdown\                                                                                                          Simvastatin reduced bone loss in a dose-dependent manner
                        EIP by ligatures\                                                                                                                                                                                                                                                                                                                                                                                                Simvastatin\                                                                                                                                                                                                                                              ↘ bone loss in alveolar bone crest zone in a dose-dependent manner\                                                               
                        Mandibular right M1                                                                                                                                                                                                                                                                                                                                                                                              10^−6^ M, 3 × 10^−7^ M, 10^−7^ M subperiosteal injections (0.05 mL)\                                                                                                                                                                                      (10^−7^ \> 10^−6^ \> 3 × 10^−7^)                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                         Twice a week since the first day of ligature insertion to the 25th day                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  \[[@B143]\]           Rat (female)\                                                                                                                                                                                                                                                                                                                                                                                                    Nonsurgical treatment (therapeutic)\                                                                                                                                                                                                                      ↗ alveolar bone crest preservation with SIM-PPi\                                                                                  Simvastatin improved periodontal bone regeneration and decreased periodontal inflammation
                        EIP (ligature)\                                                                                                                                                                                                                                                                                                                                                                                                  Simvastatin\                                                                                                                                                                                                                                              ↗ bone volume\                                                                                                                    
                        Maxillary M2 bilaterally                                                                                                                                                                                                                                                                                                                                                                                         SIM-PPi conjugate\                                                                                                                                                                                                                                        ↗ trabecular thickness\                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                         Different treatments including SIM-PPi (dissolved in 25%, 2.56 mg, equivalent to 1.5 mg SIM) and SIM acid (dissolved in PBS, 1.56 mg, equivalent to 1.5 mg of SIM) locally injected (10 *μ*L) into the palatal gingiva between the maxillary M1 and M2\   ↗ trabecular number\                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                         On the first day of weeks 1, 2 and 3 after ligature placement                                                                                                                                                                                             ↘ trabecular separation\                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ↘ neutrophil and lymphocyte score\                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ↘ OC score                                                                                                                        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

*In vivo* studies evaluating the impact of systemic statin administration on periodontal wound healing.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Systemic drug delivery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  ------------------------ -------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------
  \[[@B31]\]               Rats (male)\                                                                                                                           Nonsurgical treatment (protective)\                                                                                                                                                                                                                                                                                                                                          ↘ MMP-2, MMP-9\                                                                                                                                             Atorvastatin protected against alveolar bone loss in a dose-dependent manner
                           EIP by ligatures\                                                                                                                      Atorvastatin\                                                                                                                                                                                                                                                                                                                                                                ↘ RANK-L, RANK\                                                                                                                                             
                           Maxillary left M2                                                                                                                      1 mg/kg, 5 mg/kg, and 10 mg/kg\                                                                                                                                                                                                                                                                                                                                              ↗ OPG\                                                                                                                                                      
                                                                                                                                                                  1 hour before induction and thereafter once daily                                                                                                                                                                                                                                                                                                                            ↗ GSH levels\                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ↘ IL-1*β*, TNF-*α*, and MPO (dose dependent)\                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ↘ COX-2 level\                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ↘ MDA activity\                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ↘ alveolar bone loss is dose dependent                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B58]\]               Rats (female)\                                                                                                                         Nonsurgical treatment (protective)\                                                                                                                                                                                                                                                                                                                                          ↗ BMP-2 and OPG levels\                                                                                                                                     Simvastatin prevented inflammatory bone resorption and possessed antioxidant properties
                           EIP by ligatures\                                                                                                                      Simvastatin 3, 10, and 30 mg/kg/day\                                                                                                                                                                                                                                                                                                                                         ↗ TRAP activity\                                                                                                                                            
                           Maxillary left M2                                                                                                                      1 hour before induction and thereafter once daily                                                                                                                                                                                                                                                                                                                            ↘ MPO activity (dose dependent)\                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ↘ IL-1*β* and TNF-*α*\                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ↗ IL-10\                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ↘ gingival GSH\                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ↗ gingival MDA and NOX\                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ↘ iNOS, MMP-1, MMP-8, RANK, and RANKL expression\                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               No differences in AST and ALT levels\                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Inhibition of alveolar bone loss                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B144]\]              Rats (male)\                                                                                                                           Nonsurgical treatment (protective)\                                                                                                                                                                                                                                                                                                                                          ↘ alveolar bone loss\                                                                                                                                       Atorvastatin had protective effect against alveolar bone loss
                           EIP by ligatures\                                                                                                                      Atorvastatin\                                                                                                                                                                                                                                                                                                                                                                in the furcation area as well as in proximal faces of upper M2\                                                                                             
                           Maxillary left M2                                                                                                                      1, 3, and 9 mg/kg\                                                                                                                                                                                                                                                                                                                                                           (47% reduction with 9 mg dose compared to that with the control)\                                                                                           
                                                                                                                                                                  Atorvastatin mixed in sterile saline by gavage\                                                                                                                                                                                                                                                                                                                              Insignificant bone loss protection with 1 and 3 mg doses                                                                                                    
                                                                                                                                                                  30 min before ligature placement and then daily until euthanasia                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B40]\]               Rats (male)\                                                                                                                           Nonsurgical treatment (protective + therapeutic)\                                                                                                                                                                                                                                                                                                                            ↘ TRAP and MPO activity\                                                                                                                                    Atorvastatin reduced alveolar bone loss, cemental resorption, and inflammatory cell infiltration both prophylactically and therapeutically
                           EIP by ligatures\                                                                                                                      Atorvastatin 0.3 mg/kg or 27 mg/kg by gavage\                                                                                                                                                                                                                                                                                                                                ↘ cementum resorption\                                                                                                                                      
                           Maxillary left M2                                                                                                                      In combination with ALN\                                                                                                                                                                                                                                                                                                                                                     ↘ neutrophilia and lymphomonocytosis\                                                                                                                       
                                                                                                                                                                  30 min before ligature placement and thereafter once daily until euthanasia or 5 days after the start of periodontitis induction and then daily until euthanasia                                                                                                                                                                                                             ↘ alveolar bone loss both prophylactically (39%) and therapeutically (53.4%) with lower dose of ALN + ATV (0.01 mg/kg+0.3 mg/kg, respectively)\             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Prevented BALP reduction with lower dose of ALN + ATV\                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               No effect on serum transaminases                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B145]\]              Rats (male)\                                                                                                                           Nonsurgical treatment (protective)\                                                                                                                                                                                                                                                                                                                                          ↘ alveolar bone in a dose-dependent manner (39% for 3 mg/kg and 56% for 27 mg/kg doses)\                                                                    Atorvastatin prevented alveolar bone loss with both prophylactic and therapeutic doses
                           EIP by ligatures\                                                                                                                      Atorvastatin 0.3, 3, and 27 mg/kg by gavage\                                                                                                                                                                                                                                                                                                                                 Prevented the reduction of BALP serum levels (27 mg/kg)\                                                                                                    
                           Maxillary left M2                                                                                                                      30 min before ligature placement and thereafter once daily until euthanasia                                                                                                                                                                                                                                                                                                  Prevented leukocytosis (27 mg/kg)                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B32]\]               Rats (female with metabolic syndrome)\                                                                                                 Nonsurgical treatment (protective)\                                                                                                                                                                                                                                                                                                                                          ↘ LPS induced alveolar bone loss in both lean and fat rats (significantly)\                                                                                 Simvastatin downregulated inflammation-mediated bone resorption
                           ACP (injection of 20 *μ*g of *A.a* LPS in PBS) into the palatal gingiva between the maxillary M1 and M2, thrice per week for 4 weeks   Simvastatin 20 mg/kg/day\                                                                                                                                                                                                                                                                                                                                                    ↘ infiltration of mononuclear cells\                                                                                                                        
                                                                                                                                                                  Daily via gavage for 4 weeks\                                                                                                                                                                                                                                                                                                                                                ↘ inflammatory score\                                                                                                                                       
                                                                                                                                                                  Treatment started on the same day as injection of LPS                                                                                                                                                                                                                                                                                                                        ↘ LPS stimulated RANKL and CSF2 expression in both lean and fat rats\                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ↘ bone resorption                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B33]\]               Rats (female)\                                                                                                                         Nonsurgical treatment (protective)\                                                                                                                                                                                                                                                                                                                                          ↘ LPS induced alveolar bone loss (31%)\                                                                                                                     Simvastatin downregulated inflammation-mediated bone resorption
                           *ACP injection of* 20 *μ*g/rat of *A.a*\                                                                                               Simvastatin (20 mg/kg/day) daily via oral gavage for 8 weeks                                                                                                                                                                                                                                                                                                                 ↘ LPS induced osteoclastogenesis\                                                                                                                           
                           LPS through the palatal gingiva between the maxillary M1 and M2 thrice per week for 8 weeks                                                                                                                                                                                                                                                                                                                                                                                                                         ↘ TNF-*α*, IL-1*α*, IL-1*β*, IL-6, CSF-2, CSF-3, MCP-1, and MMP-9\                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ↘ LPS induced TLR family members\' expression                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B25]\]               Rats (male)\                                                                                                                           Nonsurgical treatment (protective)\                                                                                                                                                                                                                                                                                                                                          ↗ IL-10\                                                                                                                                                    Rosuvastatin protected against alveolar bone loss
                           EIP by ligatures\                                                                                                                      Rosuvastatin\                                                                                                                                                                                                                                                                                                                                                                ↘ IL-1*β*\                                                                                                                                                  
                           Maxillary M2                                                                                                                           20 mg/kg in water by gavage\                                                                                                                                                                                                                                                                                                                                                 ↗ MDA\                                                                                                                                                      
                                                                                                                                                                  1 h before ligation and then once daily until euthanasia                                                                                                                                                                                                                                                                                                                     ↗ GSH\                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ↘ inflammatory infiltrate\                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ↘ OC number\                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ↗ OB number\                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ↘ alveolar bone loss (significantly)                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B54]\]               Rats (male)\                                                                                                                           Nonsurgical treatment (protective)\                                                                                                                                                                                                                                                                                                                                          ↘ gingival iNOS (significantly)\                                                                                                                            Rosuvastatin protected against inflammation-induced bone degradation
                           EIP by ligatures\                                                                                                                      Rosuvastatin\                                                                                                                                                                                                                                                                                                                                                                ↘ inflammation and hyperemia\                                                                                                                               
                           Hyperlipidemia induction through diet\                                                                                                 20 mg/kg in water by gavage\                                                                                                                                                                                                                                                                                                                                                 ↘ alveolar bone loss                                                                                                                                        
                           Maxillary M2                                                                                                                           1 h before ligation and then once daily until euthanasia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B34]\]               Rats (male)\                                                                                                                           Nonsurgical treatment (therapeutic)\                                                                                                                                                                                                                                                                                                                                         ↘ alveolar bone loss\                                                                                                                                       Simvastatin decreased inflammation and alveolar bone loss
                           EIP by ligatures\                                                                                                                      Simvastatin\                                                                                                                                                                                                                                                                                                                                                                 ↘ IL-6\                                                                                                                                                     
                           Mandibular M1 and maxillary M2 bilaterally                                                                                             10 mg/kg in water once daily orally until euthanasia\                                                                                                                                                                                                                                                                                                                        ↘ CRP                                                                                                                                                       
                                                                                                                                                                  Treatment started 8 days after periodontitis induction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B93]\]               Rats (male hypertensive)\                                                                                                              Nonsurgical treatment (protective)\                                                                                                                                                                                                                                                                                                                                          ↘ bone loss in furcation area\                                                                                                                              Rosuvastatin reduced alveolar bone loss and osteoclastogenesis
                           EIP by ligatures\                                                                                                                      Rosuvastatin\                                                                                                                                                                                                                                                                                                                                                                ↘ attachment loss\                                                                                                                                          
                           Mandibular M1 bilaterally                                                                                                              2 mg/kg oral gavage\                                                                                                                                                                                                                                                                                                                                                         ↘ TRAP-positive multinucleated cells                                                                                                                        
                                                                                                                                                                  Treatment started since the day of induction daily until euthanasia                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B97]\]               Rats\                                                                                                                                  Nonsurgical treatment (protective + therapeutic)\                                                                                                                                                                                                                                                                                                                            No significant differences between groups receiving simvastatin before the induction of periodontitis and those that received water\                        Simvastatin did not possess protective or therapeutic effects against periodontitis development
                           EIP by ligatures\                                                                                                                      Simvastatin\                                                                                                                                                                                                                                                                                                                                                                 No protective effect of simvastatin against the development of periodontitis                                                                                
                           Mandibular M1                                                                                                                          Different treatments: simvastatin-simvastatin: aqueous suspension of simvastatin by gavage (35 mg/kg/day) administration before and after periodontitis induction; simvastatin-water: simvastatin administration before and filtered water after periodontitis induction; and water-simvastatin: water administration before and simvastatin after periodontitis induction                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B146]\]              Rats (male)\                                                                                                                           Nonsurgical treatment (therapeutic)\                                                                                                                                                                                                                                                                                                                                         ↗ TG levels\                                                                                                                                                Simvastatin promoted the anti-inflammatory mediators to counter alveolar bone loss
                           EIP by ligatures\                                                                                                                      Simvastatin 25 mg/kg\                                                                                                                                                                                                                                                                                                                                                        ↘ MDA level\                                                                                                                                                
                           Mandibular left M1                                                                                                                     Dissolved in saline\                                                                                                                                                                                                                                                                                                                                                         ↗ IL-10\                                                                                                                                                    
                                                                                                                                                                  Treatment started 14 days after the initiation of periodontitis induction                                                                                                                                                                                                                                                                                                    ↘ MMP-9\                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ↘ bone loss\                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               No difference on TNF-*α* levels                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B35]\]               Rats (male, cyclosporine A-induced alveolar bone loss)\                                                                                Nonsurgical treatment (protective)\                                                                                                                                                                                                                                                                                                                                          ↗ Ca2+ concentrations (significantly)\                                                                                                                      Simvastatin did not prevent alveolar bone loss in periodontitis but it completely countered the cyclosporine A-induced bone loss
                           EIP by ligatures\                                                                                                                      Simvastatin\                                                                                                                                                                                                                                                                                                                                                                 No effect of simvastatin treatment in the presence of periodontal disease on serum ALP levels but it blocked the cyclosporine A-mediated decrease of ALP\   
                           Mandibular right M1                                                                                                                    20 mg/kg orally daily\                                                                                                                                                                                                                                                                                                                                                       No significant effect on alveolar bone turnover but with concomitant cyclosporine A and simvastatin delivery\                                               
                                                                                                                                                                  for 30 days\                                                                                                                                                                                                                                                                                                                                                                 Simvastatin completely inhibited cyclosporine A-induced bone loss                                                                                           
                                                                                                                                                                  The treatment and induction started on the same day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B147]\]              Rats (male)\                                                                                                                           Nonsurgical treatment (protective)\                                                                                                                                                                                                                                                                                                                                          ↗ ALP activity in periodontal inflammation\                                                                                                                 Simvastatin protected against alveolar bone loss
                           EIP by ligatures\                                                                                                                      Simvastatin\                                                                                                                                                                                                                                                                                                                                                                 ↘ alveolar bone loss                                                                                                                                        
                           Mandibular right M1                                                                                                                    20 mg/kg\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                  The treatment and induction started on the same day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B76]\]               Mice (male)\                                                                                                                           Nonsurgical treatment (protective)\                                                                                                                                                                                                                                                                                                                                          ↘ LPS induced OC (by \>50%)\                                                                                                                                Fluvastatin prevented inflammation-induced bone erosion
                           ACP (*P.g* LPS injection)\                                                                                                             Fluvastatin 3 mg/kg\                                                                                                                                                                                                                                                                                                                                                         ↘ LPS-induced bone erosion\                                                                                                                                 
                           1 mg/kg *P.g* LPS\                                                                                                                     IP injections on days 1, 4, and 7                                                                                                                                                                                                                                                                                                                                            ↘ RANKL                                                                                                                                                     
                           injection at the gingiva of left mandibular M2 on days 4 and 7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B26]\]               Rats (male, GIOP)\                                                                                                                     Nonsurgical treatment (protective)\                                                                                                                                                                                                                                                                                                                                          ↘ bone loss\                                                                                                                                                Atorvastatin prevented alveolar bone loss in periodontitis and reduced inflammation
                           EIP by ligatures Maxillary left M2                                                                                                     Atorvastatin\                                                                                                                                                                                                                                                                                                                                                                ↘ MPO, TNF-*α*, IL-1*β*, IL-6, and IL-8\                                                                                                                    
                                                                                                                                                                  27 mg/kg ATV orally\                                                                                                                                                                                                                                                                                                                                                         ↗ IL-10, GSH, SOD, and CAT levels\                                                                                                                          
                                                                                                                                                                  30 min before induction and once daily afterwards                                                                                                                                                                                                                                                                                                                            ↘ RANKL and DKK-1\                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ↗ OPG, WNT10 *β*, and *β*-catenin expressions and BALP activity                                                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

*In vivo* studies evaluating the impact of a combination of local and systemic statin administration on periodontal wound healing.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Local + systemic drug delivery                                                                                                                                                                                                                                                       
  -------------------------------- --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  \[[@B57]\]                       Rats (male)\                      Nonsurgical treatment (therapeutic)\                                                                                                        ↗ alveolar bone area %\                                               Atorvastatin increased the alveolar bone regeneration while decreasing the periodontal inflammation and attachment loss
                                   EIP by ligature mandibular M1     Atorvastatin\                                                                                                                               ↗ VEGF\                                                               
                                                                     Systemically (5 mg/kg in a volume of 0.5 mL) and locally (0.1 mg/kg in a volume of 0.05 mL) at a dose of 0.1 mg/kg in a volume of 0.05 mL   ↘ MMP-9\                                                              
                                                                                                                                                                                                                 ↘ alveolar bone and attachment loss\                                  
                                                                                                                                                                                                                 Local application showed better results on periodontium healing       

                                                                                                                                                                                                                                                                                       

  \[[@B92]\]                       Rats (female ovarectomized)\      Nonsurgical treatment (therapeutic)\                                                                                                        ↗ alveolar crest height (28% with local & oral and 27% with local)\   Simvastatin reduced bone degradation when administered locally, systemically, or both locally and systemically together
                                   EIP by ligatures\                 Simvastatin\                                                                                                                                ↗ BV/TV\                                                              
                                   Maxillary M1 and M2 bilaterally   Local injection (0.8 mg/0.05 mL)\                                                                                                           ↗ trabecular thickness\                                               
                                                                     Oral (25 mg/kg)\                                                                                                                            ↘ trabecular separation                                               
                                                                     For two months until euthanasia                                                                                                                                                                                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The animals included in the studies are healthy unless stated otherwise. Treatment was considered (1) "preventative" when it started at least one day before the start of EIP/ACP induction, (ii) "protective" when it started the same day as that of EIP/ACP induction, and (iii) "therapeutic" when it started at least one day after the start of EIP/ACP induction.

###### 

Clinical studies evaluating the impact of local statin administration on periodontal wound healing.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Local drug delivery                                                                                                                                                                                                                                                                                                                                                                                                                                       
  -------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \[[@B130]\] (India)\                   Simvastatin in methylcellulose gel\                                                                     30\                                                                                                                Nonsurgical treatment\                                  All subjects tolerated the drug\                                                                                                Simvastatin increased periodontal regeneration and CAL gain
  RCT with split-mouth design            1.2 g of SIM                                                                                            Periodontitis (Armitage 1999)\                                                                                     Group I: SRP + placebo gel\                             ↗ periodontal parameters with or without SIM\                                                                                   
                                                                                                                                                 Healthy patients (nonsmokers)\                                                                                     Group II: SRP + SIM gel\                                ↗ CAL (*p* = 0.02)\                                                                                                             
                                                                                                                                                 Sites with periodontal pocket measuring ≥ 5 mm and vertical bone loss ≥ 2 mm in different quadrants of the mouth   6 months follow-up                                      ↗ INFRA 2 (*p* \< 0.01)\                                                                                                        
                                                                                                                                                                                                                                                                                                                            ↘ PD significantly (*p* = 0.04)\                                                                                                
                                                                                                                                                                                                                                                                                                                            ↘ INFRA 1 (*p* \< 0.01)                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B23]\] (India)\                    Rosuvastatin\                                                                                           90\                                                                                                                Nonsurgical treatment\                                  ↗ CAL\                                                                                                                          Rosuvastatin increased periodontal regeneration and CAL gain
  RCT                                    1.2% rosuvastatin (RSV) gel                                                                             Chronic periodontitis\                                                                                             Groups I: SRP + placebo gel\                            ↘ PD significant\                                                                                                               
                                                                                                                                                 Healthy patients (nonsmokers)                                                                                      Group II: SRP + 1.2% RSV gel\                           ↗ bone fill\                                                                                                                    
                                                                                                                                                                                                                                                                    Group III: SRP + 1% MF gel\                             ↘ PI\                                                                                                                           
                                                                                                                                                                                                                                                                    12 months follow-up                                     ↘ mSBI\                                                                                                                         
                                                                                                                                                                                                                                                                                                                            ↘ DDR                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B102]\] (India)\                   Atorvastatin and rosuvastatin\                                                                          90\                                                                                                                Nonsurgical treatment\                                  ↘ PI and mSBI in all groups\                                                                                                    Statins increased periodontal regeneration and CAL gain
  RCT                                    1.2% atorvastatin or 1.2% rosuvastatin gel local drug delivery\                                         No data\                                                                                                           Group I: SRP + placebo\                                 The 2 statins lead to the following:\                                                                                           
                                         (1.2 mg/0.1 mL)                                                                                         Healthy patients (nonsmokers)\                                                                                     Group II: SRP + 1.2% RSV gel\                           ↘ PD\                                                                                                                           
                                                                                                                                                 Mandibular class II furcation defects with PD ≥ 5 mm and horizontal PD ≥ 3 mm                                      Group III: SRP + 1.2% ATV gel\                          ↗ mean gain in CAL\                                                                                                             
                                                                                                                                                                                                                                                                    9 month follow-up                                       ↗ mean percentage of DDR\                                                                                                       
                                                                                                                                                                                                                                                                                                                            Statistically greater results for RSV than for ATV                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B103]\] (India)\                   Simvastatin\                                                                                            50\                                                                                                                Nonsurgical treatment\                                  ↘ IL-6 and IL-8\                                                                                                                Simvastatin gel decreased periodontal inflammation and promote periodontal regeneration
  Cohort study                           SIM gel (1.2 mg/0.1 mL)                                                                                 Chronic periodontitis\                                                                                             Group I: SRP alone\                                     ↗ IL-10 significantly\                                                                                                          
                                                                                                                                                 Healthy patients (nonsmokers)                                                                                      Group II: SRP + SIM gel\                                ↘ PI, mSBI, and PD\                                                                                                             
                                                                                                                                                                                                                                                                    3 months follow-up                                      No effect on CAL                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B21]\] (India)\                    Simvastatin\                                                                                            46\                                                                                                                Nonsurgical treatment\                                  ↘ PI, GI, and SBI\                                                                                                              Simvastatin gel decreased periodontal inflammation
  RCT                                    1.2% simvastatin gel                                                                                    Chronic periodontitis\                                                                                             Group I: SRP\                                           No significant difference for PD and CAL\                                                                                       
                                                                                                                                                 Healthy patients (nonsmokers)                                                                                      Group II: SRP + SIM gel\                                ↘ mean IL-6 levels\                                                                                                             
                                                                                                                                                                                                                                                                    45 days follow-up                                       No significant difference for IL-8 levels                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B104]\] (India)\                   Simvastatin\                                                                                            15\                                                                                                                Surgical treatment (Kirkland flap)\                     ↘ PD\                                                                                                                           Simvastatin increased periodontal regeneration and CAL gain
  Cohort study with split-mouth design   Combination of DFDBA and a 10^−8^ M solution of the drug simvastatin                                    No data\                                                                                                           Group A: DFDBA alone\                                   ↗ mean gain in CAL (better with DFDBA + SIM)\                                                                                   
                                                                                                                                                 Healthy patients (nonsmokers)\                                                                                     Group B: DFDBA + SIM\                                   ↘ infrabony defect depth (greater reduction with DFDBA + SIM)\                                                                  
                                                                                                                                                 Identical bilateral infrabony defect                                                                               24 weeks follow-up                                      ↗ linear defect fill (better with DFDBA + SIM)                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B148]\] (India)\                   Atorvastatin\                                                                                           75\                                                                                                                Nonsurgical treatment\                                  ↗ mSBI\                                                                                                                         Atorvastatin increased periodontal regeneration
  RCT                                    1.2% atorvastatin gel (ATV gel (1.2 mg/0.1 mL)                                                          Well-controlled type 2 diabetic patients (nonsmokers)\                                                             Group 1: SRP + ATV\                                     ↘ PD\                                                                                                                           
                                                                                                                                                 Chronic periodontitis                                                                                              Group 2: SRP + placebo\                                 ↗ CAL gain\                                                                                                                     
                                                                                                                                                                                                                                                                    9 months follow-up                                      ↘ IBD depth and DDR\                                                                                                            
                                                                                                                                                                                                                                                                                                                            No significant difference for PI at all time intervals evaluated                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B125]\] (India)\                   Atorvastatin\                                                                                           71\                                                                                                                Nonsurgical treatment\                                  ↘ PD\                                                                                                                           Atorvastatin increased periodontal regeneration and CAL gain
  RCT                                    1.2% atorvastatin gel (ATV gel (1.2 mg/0.1 mL))                                                         Smokers\                                                                                                           Group 1: SRP + ATV\                                     ↗ mean CAL gain\                                                                                                                
                                                                                                                                                 Chronic periodontitis                                                                                              Group 2: SRP + placebo\                                 ↘ mean percentage of DDR\                                                                                                       
                                                                                                                                                                                                                                                                    9 months follow-up                                      ↘ mSBI\                                                                                                                         
                                                                                                                                                                                                                                                                                                                            ↘ IBD depth\                                                                                                                    
                                                                                                                                                                                                                                                                                                                            No statistically significant difference in the site-specific PI score and full-mouth PI score between the groups at any visit   

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B105]\] (India)\                   Atorvastatin\                                                                                           96\                                                                                                                Surgical treatment\                                     ATV gel and PRF alone showed significantly the following:\                                                                      Atorvastatin increased periodontal regeneration and CAL gain
  Cohort                                 1.2% ATV gel                                                                                            Healthy patients (nonsmokers)\                                                                                     Group I: OFD + PRF\                                     ↘ PD\                                                                                                                           
                                                                                                                                                 Chronic periodontitis                                                                                              Group II: OFD + PRF + 1.2% ATV\                         ↗ mean CAL gain\                                                                                                                
                                                                                                                                                                                                                                                                    Group III: OFD alone\                                   ↘ IBD depth\                                                                                                                    
                                                                                                                                                                                                                                                                    9 months follow-up                                      No statistically significant difference in PI and mSBI scores between the groups at 9 months                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B101]\] (India)\                   Atorvastatin and simvastatin\                                                                           96\                                                                                                                Nonsurgical treatment\                                  The 2 statins lead to the following:\                                                                                           Atorvastatin increased periodontal regeneration and CAL gain
  RCT                                    10 mL of 1.2% ATV gel (1.2 mg/0.1 mL) and 10 mL of 1.2% SIM gel (1.2 mg/0.1 mL)                         Healthy patients (nonsmokers)\                                                                                     Group I: SRP + 1.2% ATV\                                ↘ PD\                                                                                                                           
                                                                                                                                                 Chronic periodontitis                                                                                              Group II: SRP + 1.2% SIM\                               ↘ mSBI\                                                                                                                         
                                                                                                                                                                                                                                                                    Group III: SRP + placebo\                               ↘ IBD depth\                                                                                                                    
                                                                                                                                                                                                                                                                    9 months follow-up                                      ↗ mean CAL gain\                                                                                                                
                                                                                                                                                                                                                                                                                                                            Statistically greater results for ATV than for SIM for PD reduction, CAL gain and percentage of IBD reduction                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B149]\] (India)\                   Simvastatin\                                                                                            60\                                                                                                                Nonsurgical treatment\                                  ↘ mSBI\                                                                                                                         Simvastatin increased periodontal regeneration and CAL gain
  RCT                                    Single topical transmucosal injection 1.2 mg SIM                                                        Chronic periodontitis\                                                                                             Group I: SRP + placebo\                                 ↘ mean PD\                                                                                                                      
                                                                                                                                                 Healthy patients (nonsmokers)                                                                                      Group II: SRP + SIM\                                    ↗ mean CAL\                                                                                                                     
                                                                                                                                                                                                                                                                    6 months follow-up                                      ↗ IBD fill\                                                                                                                     
                                                                                                                                                                                                                                                                                                                            ↘ GI                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B126]\] (India)\                   Simvastatin\                                                                                            72\                                                                                                                Nonsurgical treatment\                                  ↘ SBI and PB\                                                                                                                   Simvastatin increased periodontal regeneration and CAL gain
  RCT                                    SIM 1.2 *μ*g/inj. (0.12 *μ*g/mm3)\                                                                      Chronic periodontitis\                                                                                             Group I: SRP + placebo\                                 ↗ CAL\                                                                                                                          
                                         Methylcellulose gel                                                                                     Healthy patients (nonsmokers)\                                                                                     Group II: SRP + 1.2 mg SIM\                             ↗ IBD fill                                                                                                                      
                                                                                                                                                 Mandibular buccal class II furcation defects                                                                       6 months follow-up                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B150]\] (India)\                   Atorvastatin\                                                                                           60 patients\                                                                                                       Nonsurgical treatment\                                  ↘ PD\                                                                                                                           Simvastatin increased periodontal regeneration and CAL gain
  RCT                                    1.2% ATV methyl cellulose gel                                                                           Chronic periodontitis\                                                                                             Group I: SRP + 1.2% ATV\                                ↘ mSBI\                                                                                                                         
                                                                                                                                                 Healthy patients (nonsmokers)                                                                                      Groups II: SRP + placebo gel\                           ↗ mean CAL gain\                                                                                                                
                                                                                                                                                                                                                                                                    9 months follow-up                                      ↗ IBD fill                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B151]\] (India)\                   Simvastatin\                                                                                            38\                                                                                                                Nonsurgical treatment\                                  ↘ PD\                                                                                                                           Simvastatin increased periodontal regeneration and CAL gain
  RCT                                    1.2% SIM gel                                                                                            Chronic periodontitis\                                                                                             Group I: SRP + SIM\                                     ↗ mean CAL gain\                                                                                                                
                                                                                                                                                 Well-controlled type II diabetes\                                                                                  Group II: SRP + placebo\                                ↗ mean radiographic bone fill\                                                                                                  
                                                                                                                                                 Nonsmokers                                                                                                         9 months follow-up                                      ↘ mSBI                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B152]\] (India)\                   Rosuvastatin\                                                                                           65\                                                                                                                Nonsurgical treatment\                                  ↘ mSBI\                                                                                                                         Rosuvastatin increased periodontal regeneration and CAL gain
  RCT                                    1.2% rosuvastatin (RSV) gel                                                                             Chronic periodontitis\                                                                                             Group I: SRP + RSV\                                     ↘ PD\                                                                                                                           
                                                                                                                                                 Healthy (nonsmokers)                                                                                               Group II: SRP + placebo\                                ↗ mean CAL gain\                                                                                                                
                                                                                                                                                                                                                                                                    6 months follow-up                                      ↗ IBD fill                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B20]\] (India)\                    Atorvastatin + rosuvastatin\                                                                            90\                                                                                                                Nonsurgical treatment\                                  The 2 statins lead to the following:\                                                                                           Atorvastatin and rosuvastatin increased periodontal regeneration and CAL gain
  RCT                                    1.2% RSV and 1.2% ATV gel                                                                               Chronic periodontitis\                                                                                             Group I: SRP + placebo\                                 ↘ mSBI\                                                                                                                         
                                                                                                                                                 Healthy (nonsmokers)                                                                                               Group II: SRP + 1.2% RSV gel\                           ↘ PD\                                                                                                                           
                                                                                                                                                                                                                                                                    Group III: SRP + 1.2% ATV gel\                          ↗ mean CAL gain\                                                                                                                
                                                                                                                                                                                                                                                                    9 months follow-up                                      ↗ IBD fill\                                                                                                                     
                                                                                                                                                                                                                                                                                                                            Statistically greater results for RSV than for ATV for PD reduction, CAL gain, IBD reduction, and msSBI reduction               

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B106]\] (India)\                   Rosuvastatin\                                                                                           90\                                                                                                                Surgical treatment\                                     ↘ PD\                                                                                                                           Rosuvastatin increased periodontal regeneration and CAL gain
  RCT                                    1.2% RSV gel                                                                                            Chronic periodontitis\                                                                                             2/3-walled intrabony defects\                           ↗ mean CAL gain\                                                                                                                
                                                                                                                                                 Healthy (nonsmokers)                                                                                               Group I: OFD alone\                                     ↗ IBD fill                                                                                                                      
                                                                                                                                                                                                                                                                    Group II: OFD + PRF\                                                                                                                                                                    
                                                                                                                                                                                                                                                                    Group III: OFD + PRF + 1.2% RSV gel\                                                                                                                                                    
                                                                                                                                                                                                                                                                    9 months follow-up                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B107]\] (India)\                   Rosuvastatin\                                                                                           110\                                                                                                               Surgical treatment\                                     ↘ PD\                                                                                                                           Rosuvastatin increased periodontal regeneration and CAL gain
  RCT                                    1.2% RSV gel                                                                                            Chronic periodontitis\                                                                                             Group 1: OFD + placebo gel\                             ↗ mean CAL gain\                                                                                                                
                                                                                                                                                 Healthy (nonsmokers)\                                                                                              Group II: OFD + PRF + HA\                               ↗ IBD fill\                                                                                                                     
                                                                                                                                                 Mandibular degree II furcation defects                                                                             Group III: OFD + RSV 1.2 mg gel + PRF + HA\             ↘ PI and mSBI                                                                                                                   
                                                                                                                                                                                                                                                                    9 months follow-up                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B153]\] (India)\                   Atorvastatin\                                                                                           90\                                                                                                                Nonsurgical treatment\                                  ↘ PD\                                                                                                                           Local delivery of atorvastatin increased periodontal regeneration
  RCT                                    1.2% atorvastatin gel                                                                                   Chronic periodontitis\                                                                                             Group I: SRP + ALN\                                     ↗ mean CAL gain\                                                                                                                
                                                                                                                                                 Healthy patients (nonsmokers)\                                                                                     Group II: SRP + 1.2% ATV\                               ↗ IBD fill\                                                                                                                     
                                                                                                                                                 Intrabony defect                                                                                                   Group III: SRP + placebo group\                         ↘ mSBI                                                                                                                          
                                                                                                                                                                                                                                                                    9 months follow-up                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B154]\] (India)\                   Simvastatin\                                                                                            24\                                                                                                                Nonsurgical treatment\                                  ↘ PD\                                                                                                                           Simvastatin increased periodontal regeneration
  RCT                                    0.1 mL SIM gel (1.2 mg/0.1 mL)                                                                          Aggressive periodontitis\                                                                                          Group I: SRP + placebo gel\                             ↗ mean CAL gain\                                                                                                                
                                                                                                                                                 Healthy patients (nonsmokers)\                                                                                     Group II: SRP + SIM gel\                                ↗ IBD fill\                                                                                                                     
                                                                                                                                                 Intrabony defect                                                                                                   6 months follow-up                                      ↘ mSBI\                                                                                                                         
                                                                                                                                                                                                                                                                                                                            All patients tolerated the drug with no postapplication complications\                                                          
                                                                                                                                                                                                                                                                                                                            No statistically significant difference between groups I and II regarding PI                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B108]\] (India)\                   Simvastatin\                                                                                            20\                                                                                                                Surgical treatment\                                     ↗ IBD fill for group I\                                                                                                         Simvastatin increased periodontal regeneration
  RCT                                    1.2 mg Simvastatin gel                                                                                  Chronic periodontitis\                                                                                             PD ≥ 5 mm in the mandibular molar region bilaterally\   Significant results at 9 months in both groups:\                                                                                
                                                                                                                                                 Healthy patients (nonsmokers)                                                                                      Group I: OFD + SIM\                                     ↘ GI, PD\                                                                                                                       
                                                                                                                                                                                                                                                                    Group II: OFD + placebo gel\                            ↗ mean CAL gain                                                                                                                 
                                                                                                                                                                                                                                                                    9 months follow-up                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B155]\] (India)\                   Simvastatin\                                                                                            40\                                                                                                                Nonsurgical treatment\                                  ↘ mSBI\                                                                                                                         Simvastatin increased periodontal regeneration and CAL gain
  RCT                                    10 *μ*L prepared SIM gel (1.2 mg/0.1 mL)                                                                Chronic periodontitis\                                                                                             Group I: SRP + SIM 1.2%\                                ↘ PD\                                                                                                                           
                                                                                                                                                 Healthy patients\                                                                                                  Group II: SRP + placebo\                                ↗ mean CAL gain\                                                                                                                
                                                                                                                                                 Smokers only                                                                                                       9 months follow-up                                      ↗ IBD fill                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B156]\] (India)\                   Simvastatin\                                                                                            60\                                                                                                                Nonsurgical treatment\                                  ↘ mSBI and PD\                                                                                                                  This study showed the efficacy of SIM as a local drug delivery system in the treatment of chronic periodontitis not only in clinical but also in molecular levels
  RCT                                    1.2% simvastatin gel                                                                                    Chronic periodontitis\                                                                                             Group A: SRP + placebo\                                 ↗ mean CAL gain\                                                                                                                
                                                                                                                                                 Healthy (nonsmokers)                                                                                               Group B: SRP + SIM gel\                                 ↗ IBD fill\                                                                                                                     
                                                                                                                                                                                                                                                                    6 months follow-up                                      ↘ IL-6 levels                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B137]\] (Chile)\                   Atorvastatin\                                                                                           36\                                                                                                                Nonsurgical treatment\                                  ↘ PISA\                                                                                                                         Simvastatin increased periodontal regeneration and CAL gain
  RCT                                    2% atorvastatin dentifrice                                                                              Chronic periodontitis\                                                                                             Group I: SRP + ATV dentifrice\                          ↘ mean PD\                                                                                                                      
                                                                                                                                                 Controlled diabetic only\                                                                                          Group II: SRP + placebo dentifrice\                     ↘ % of sites with PD ≥ 5 mm\                                                                                                    
                                                                                                                                                 All types of smoking status                                                                                        1 month follow-up                                       ↗ mean CAL gain\                                                                                                                
                                                                                                                                                                                                                                                                                                                            ↘ % of sites with CAL ≥ 5 mm\                                                                                                   
                                                                                                                                                                                                                                                                                                                            ↘ BOP\                                                                                                                          
                                                                                                                                                                                                                                                                                                                            ↘ GI                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \[[@B100]\] (India)\                   Atorvastatin + simvastatin\                                                                             45\                                                                                                                Nonsurgical treatment\                                  The test groups did not show any statistically significant difference when compared with the control group                      No significant benefit for periodontal regeneration with the use of statin
  Cohort study                           Drug in sodium alginate suspension administered with calcium chloride solution, subgingival delivery\   Moderate to severe chronic periodontitis\                                                                          Group I: SRP alone\                                                                                                                                                                     
                                         1.2% simvastatin, or 1.2% atorvastatin                                                                  Healthy (nonsmokers)                                                                                               Group II: SRP + 1.2% SIM\                                                                                                                                                               
                                                                                                                                                                                                                                                                    Group III: SRP + 1.2% ATV\                                                                                                                                                              
                                                                                                                                                                                                                                                                    6 months follow-up                                                                                                                                                                      
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Clinical studies evaluating impact of systemic statin administration on periodontal wound healing.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Systemic drug delivery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  ---------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------
  \[[@B109]\] (USA)\           Not reported                                                                                                                                          1021\                                                                                     Nonsurgical treatment\                                      Any statin use during the first 3 years after the initial periodontal exam was associated with a 48% decreased tooth loss rate in year 4 and subsequent years   Statins reduced tooth loss in chronic periodontitis
  Retrospective cohort study                                                                                                                                                         Chronic periodontal disease\                                                              Hyperlipidemic vs healthy\                                                                                                                                                                                                  
                                                                                                                                                                                     All types of patients (diabetic, smokers, antibiotic users, anti-inflammatory users...)   Mean follow-up = 7.1 years                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B112]\] (Mexico)\        Atorvastatin\                                                                                                                                         38\                                                                                       Nonsurgical treatment\                                      ↘ dental mobility\                                                                                                                                              Atorvastatin reduced tooth mobility and bone loss
  RCT                          20 mg/day                                                                                                                                             Chronic periodontitis\                                                                    Group I: SRP + ATV\                                         ↘ distance from the crestal alveolar bone to the cementoenamel junction                                                                                         
                                                                                                                                                                                     Healthy (all types of smoking status)                                                     Group II: SRP + placebo\                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                               3 months follow-up                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B110]\] (Turkey)\        Atorvastatin\                                                                                                                                         20\                                                                                       Nonsurgical treatment\                                      ↘ median values for the PI, GI, PD, and BOP (%)\                                                                                                                Atorvastatin reduced periodontal breakdown\
  No control group\            10 or 20 mg                                                                                                                                           Chronic periodontitis\                                                                    SRP\                                                        ↗ median value of CAL gain\                                                                                                                                     Improved periodontal health may influence metabolic control of hyperlipidemia
  Longitudinal                                                                                                                                                                       Hyperlipidemic patients (nonsmokers)                                                      6 months follow-up                                          All lipid parameters decreased after the periodontal treatment\                                                                                                 
                                                                                                                                                                                                                                                                                                                                           No comparison with the control group                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B113]\] (Turkey)\        Atorvastatin\                                                                                                                                         80\                                                                                       Nonsurgical treatment\                                      ↗ BOP\                                                                                                                                                          Systemic atorvastatin had beneficial effects on periodontal inflammation
  Cohort study                 10 or 20 mg                                                                                                                                           Chronic periodontitis\                                                                    Group I: healthy patient + SRP\                             ↘ IL-6 (serum and GCF)\                                                                                                                                         
                                                                                                                                                                                     Healthy or hyperlipidemic patients\                                                       Group II: hyperlipidemic patients + prescribed diet (HD)\   ↘ TNF-*α* (GCF) levels                                                                                                                                          
                                                                                                                                                                                     (nonsmokers)                                                                              Group III: hyperlipidemic patients + atorvastatin (HS)\                                                                                                                                                                     
                                                                                                                                                                                                                                                                               3 months follow-up                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B111]\] (Germany)\       Simvastatin (*n* = 87), lovastatin (*n* = 27), pravastatin (*n* = 53), fluvastatin (*n* = 37), atorvastatin (*n* = 34), and cerivastatin (*n* = 42)   2689\                                                                                     All types of periodontal treatment\                         No effect on PD and CAL\                                                                                                                                        Statins had the beneficial effect of protecting against tooth loss
  Cohort study                                                                                                                                                                       All types of periodontal disease\                                                         Group I: participants undergoing statin treatment\          ↘ tooth loss                                                                                                                                                    
                                                                                                                                                                                     Hyperlipidemic vs normolipidemic\                                                         Group II: patients without statins\                                                                                                                                                                                         
                                                                                                                                                                                     All types of smoking status                                                               5.3 years mean follow-up                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B56]\]\                  Simvastatin\                                                                                                                                          117\                                                                                      Nonsurgical treatment\                                      ↘ PD in diabetic patients\                                                                                                                                      Statin intake was associated with reduced PD in diabetic patients and MMP-1 level in GCF in either nondiabetic or diabetic patients
  (USA)\                       Not reported                                                                                                                                          Chronic periodontitis\                                                                    Group I: nondiabetic patients not taking statin\            ↗ CAL in nondiabetic patients\                                                                                                                                  
  Cohort study                                                                                                                                                                       Diabetic vs healthy\                                                                      Group II: nondiabetic patients taking statin\               ↘ MMP-1 level in GCF of nondiabetic and diabetic patients\                                                                                                      
                                                                                                                                                                                     All types of smoking status                                                               Group III: diabetic patients not taking statin\             No difference was found for MMP-8 and MMP-9 levels in GCF                                                                                                       
                                                                                                                                                                                                                                                                               Group IV: diabetic patients taking statin\                                                                                                                                                                                  
                                                                                                                                                                                                                                                                               6 weeks follow-up                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B114]\]\                 Atorvastatin\                                                                                                                                         107\                                                                                      Nonsurgical periodontal treatment\                          ↘ GI\                                                                                                                                                           Patients with hyperlipidemia were more prone to periodontal disease\
  (India)\                     20 mg/day                                                                                                                                             Chronic periodontitis\                                                                    Group 1: hyperlipidemic + SIM\                              Mean change in PD is negatively associated with LDL-C\                                                                                                          Statin intake had beneficial effects on periodontal inflammation
  Cohort study                                                                                                                                                                       Hyperlipidemic vs normolipidemic\                                                         Group 2: hyperlipidemic + diet\                             Mean change in GI is positively associated with HDL-C                                                                                                           
                                                                                                                                                                                     Nonsmokers                                                                                Group 3: normolipidemic patients\                                                                                                                                                                                           
                                                                                                                                                                                                                                                                               3 months follow-up                                                                                                                                                                                                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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